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Every stimulus that threatens (or is perceived as threatening to) the homeostasis of an 
organism is called a stressor (1, 2). The ability to appraise and retain or restore homeostasis 
via appropriate adaptive behavioral and physiological (stress) responses is crucial for survival 
(2). The appraisal of a stimulus as a stressor takes place in brain areas such as the amygdala, 
the hippocampus and the prefrontal cortex. An important component of the stress response is 
the secretion of glucocorticoids via the HPA axis and of catecholamines via the sympathetic 
nervous system which orchestrate a number of adaptations both in the brain and the periphery 
(2, 3). Inability to cope with stressors or prolonged exposure to them may lead to stress-related 
disorders such as depression, anxiety, post-traumatic stress disorder (PTSD), etc. As stress-
related psychopathology results in considerable societal, financial and public health 
consequences, there has been increasing interest in better diagnoses and improved treatments 
for these disorders.  
 
Amygdala-central amygdala 
The amygdala (Figure 1) plays a central role in the orchestration of fear conditioning, anxiety 
and stress responses. It consists of diverse nuclei with distinct connectivity, neurochemical 
and morphological profiles (3). Anatomically, the amygdala is divided in the central nucleus 
of the amygdala (CeA), which expresses corticotropin releasing hormone (CRH) (Figure 1b-
c), the basal nucleus of the amygdala and the lateral nucleus of the amygdala (3). It is believed 
that the basolateral nucleus (BLA), which contains primarily glutamatergic neurons (4), is the 
locus of associative learning of fear conditioning, while the CeA is the main output region of 
the amygdala, mainly involved in coordinating the expression of fear conditioning (5-7). The 
communication between the BLA and the CeA may be mediated by the intercalated cell 
masses. These are mainly GABAergic cells that are located between the BLA and the CeA 
and may play a gating role between the BLA and the CeA (8, 9). Recently, it has been shown 
that the CeA may also be involved in the learning phase of fear conditioning (10).  
Importantly, the BLA sends and receives inputs from other brain regions such as the 
hippocampus, prefrontal cortex (PFC), hypothalamus, the ventral tegmental area and the 
nucleus accumbens (11, 12). Thus, the amygdala can be involved in a wide spectrum of 
processes and behaviors such as fear, anxiety and addiction (11, 12).  
 
HPA axis 
The main neuroendocrine regulator of stress responses is the HPA axis (Figure 2). Various 
stimuli and input from brain regions such as indirect input from the CeA (13) can induce the 
production of CRH in the paraventricular nucleus of the hypothalamus (PVN) and its secretion 
in the portal vessel system to activate the corticotrophs in the anterior pituitary. There, CRH 
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stimulates the production of adrenocorticotropic hormone (ACTH) and its release into the 
blood flow. Eventually, ACTH will reach the adrenal cortex where it binds to melanocortin 2 
(MCR2) receptors and can stimulate the production of the glucocorticoids cortisol (human) or 
corticosterone (rodent). Glucocorticoids are then secreted into the blood flow and may exert a 
broad spectrum of effects, both peripherally and centrally that are mediated by two different 
receptors, the Glucocorticoid receptor (NR3C1 or GR) and the Mineralocorticoid receptor 
(NR3C2 or MR). In the central nervous system the receptors mediate the effects of the 
hormones on learning, memory and stress related behavior, as well as their inhibition of the 
expression of CRH in the PVN and ACTH in the anterior pituitary, as part of a negative 
feedback loop that prevents persistent elevation of glucocorticoid levels. 
Glucocorticoids may also result in suppression of the HPA axis via their effects in the PFC 
and the hippocampus. Activation of GR in the PFC can result to release of endocannabinoids 
(CB). CB can then decrease GABA release onto prefrontal pyramidal cells which in turn 
increases glutamatergic input to the hypothalamus and inhibits the HPA axis (14-16). GR 
knockdown in the PFC may result in increased HPA axis responses to acute stress (17). 
Similarly, glucocorticoids in the ventral hippocampus also result in inhibition of the HPA axis 
stress responses (15).   
Apart from activation by stressful situations, glucocorticoids are also secreted in a circadian 
fashion organized by inputs from the suprachiasmatic nucleus (SCN) to the PVN (18, 19). The  
Figure 1. A. Fluorescent image of a mouse brain section stained with hoechst (blue) (10X magnification). 
The white box indicates the location of the central amygdala. B. The white box from picture A in 
magnification. CRH positive cells are immunofluorescently labeled red, while their nuclei are stained 
with Hoechst (blue) (63X magnification).  C. In situ hybridization for CRH mRNA (red) and GR mRNA 




 circadian rhythm of the glucocorticoids consists of hourly pulses of the hormone that have 
their largest amplitude at the start of the active period. (19). The stress-induced secretion of 
glucocorticoids is superimposed on these rhythms and its magnitude depends on the phase of 
the pulse (20-22). 
 
CRH 
CRH is a 41-amino acid peptide which was discovered in hypothalamic extracts in 1981 by 
W.W. Vale and was shown to stimulate the production of ACTH by cultured pituitary cells 
(23). CRH shows a wide expression pattern in stress-relevant areas in the brain including the 
PVN, the CeA, the bed nucleus of the stria terminalis, the prefrontal cortex and the 
hippocampus (24, 25). It plays a pivotal role in the regulation of glucocorticoid levels via its 
secretion from the PVN, in response to stress, while it orchestrates behavioral stress responses 
in the central amygdala (26). In line with these functions, its expression is tightly regulated by 
glucocorticoids. Interestingly, this regulation is region-specific: in the CeA the CRH 
expression is upregulated after treatment with glucocorticoids, whereas in the PVN it is 
downregulated, as part of the HPA axis’ negative feedback loop (24, 27-29). CRH 
overexpression may result in increased anxiety behavior (30, 31), while, the crh promoter is 
epigenetically regulated in response to several stimuli including treatment with 
glucocorticoids, maternal deprivation and stress (27, 32-34).  
Figure 2. The Hypothalamus-Pituitary-Adrenal axis: In response to a variety of stimuli, such as indirect 
input from the central amygdala (CeA), corticotropin releasing hormone (CRH) is secreted from the 
paraventricular nucleus of the hypothalamus (PVN) into the pituitary stimulates the expression and 
secretion of adrenocorticotropin hormone which reaches the adrenal cortex and stimulates the production 
of corticosterone. Corticosterone, in turn, represses the expression of CRH and ACTH in the PVN and 
pituitary, respectively. Glucocorticoids in the mPFC and the ventral hippocampus also result in inhibition 
of the HPA axis. 
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GR and MR 
GR and MR are nuclear receptors. All nuclear receptors consist of functional domains that can 
be directly coupled to their function as transcription factors. The relationship between the 
structure and the function of the GR (and MR) has been extensively studied (35, 36). In short, 
the GR protein contains domains that arise from eight exons (2-9, exon 1 of the mRNA is not 
translated): exon 2 codes for the N-terminal half of the protein which contains the major 
transcriptional activation domain τ1, exons 3 and 4 code for the central part of the protein 
which contains two zinc fingers involved in DNA binding and homodimerization. The C-
terminal region of the protein, encoded by exons 5-9, include among others, the domains 
responsible for transcriptional activation (τ2) and ligand binding (Figure 3a) (35-37).  
In the absence of ligand, MR and GR are bound to chaperone protein complexes in the 
cytoplasm. Upon ligand binding, a conformational change takes place that leads to the 
dimerization of the nuclear receptor and its translocation to the nucleus. There, with the 
assistance of coregulators, the nuclear receptor can bind to glucocorticoid response elements 
(GREs) on the DNA and activate or repress the expression of specific genes. The receptors are 
thought to mainly form homodimers, act as monomers in conjunction with other, non-receptor, 
transcription factors, or heterodimerize with other steroid receptors (38, 39). The activity of 
receptors depends also on the type and local concentration of the ligand (40, 41) and on the 
pattern of ligand exposure in time (42). However, additional regulation can take place at 
multiple levels. These may include the expression levels of the receptor (43), its 
posttranslational modifications (44), its interactions with molecular chaperones in the 
cytoplasm (45, 46), dimerization and translocation to the nucleus (47), the presence and 
function of kinases, such as SGK-1 (48), DNA binding and its interactions with proteins 
involved in transcription, either transcription factors or coregulator proteins (49). 
Transcription factors that bind to regulatory DNA in conjunction with GR (and to a much 
lesser extent MR) are being discovered at a substantial rate by genome wide localization of 
receptor binding using ChIP-sequencing, and subsequent statistical analysis of DNA motifs 
that overlap with or surround the receptor binding sites. Some of the identified transcription 
factors will bring the receptors to the DNA by way of ‘tethering’ mechanisms, like those 
involved in classic transrepression in the immune system (50). There are also those 
transcription factors that bind in the vicinity (within hundreds of base pairs) of the steroid 
receptors, and are in some way involved in modulating their function. In generic cell lines, AP
-1 has been shown to act as a ‘pioneer’ and make the DNA accessible for GR binding through 
chromatin modification (51). The exact nucleotide content of the GRE is associated with GR’s 
dependence on such priming mechanisms. 
It is also conceivable, or even likely, that factors that bind in the vicinity of MR and GR 
interact functionally in larger complexes on the DNA, analogous to what happens at composite 
GREs where GR binds directly adjacent to other transcription factors (52). In the rat 
hippocampus, it has been shown that GC-rich motifs for transcription factors MAZ1 and SP1 
occur in conjunction with GR binding to the DNA, suggesting either a pioneering function, or 




GR were published for neuronally differentiated PC12 cells. Interestingly, GR binding 
occurred in the vicinity of AP-1 sites, as expected, but the authors also described recognition 
sites for a number of completely new transcription factors in the vicinity of GR binding. These 
data suggest that the effects of GR (and MR) are modified by other signalling pathways that 
we are just beginning to discover (54).  
 
Coregulators 
GR and MR make use of so called nuclear receptor coregulators, a large and rather diverse 
group of proteins that are involved in transcriptional modulation. The coregulator proteins do 
not interact with the DNA (i.e. they are not transcription factors), but mediate and modulate 
the effects of transcription factors on actual transcription. Individual coregulators may interact 
with either one or several members of the nuclear receptor superfamily. Some of these 
coregulators are also important for neuronal plasticity per se and they may form a substrate for 
the modifying effects of MR and GR on neuronal plasticity. 
The recruitment of coregulators by nuclear receptors may take place in a cell-type- and 
promoter-specific manner (55). These interactions can regulate the stability of the 
transcriptional machinery, lead to recruitment of additional transcription factors and 
transcriptional coactivators or corepressors, and acetylate or deacetylate DNA histones either 
by intrinsic histone (de)acetylase activity or by recruitment of histone (de)acetylases. Histone 
acetyltransferases (HATs) are proteins that can catalyze the addition of an acetyl group to 
Lysine residues of histones. Histone acetylation may promote gene transcription via chromatin 
availability and binding of transcription factors (56). This model indicates that coregulators do 
not act in isolation but in protein complexes that may involve transcription factors, coregulator
-coregulator interactions and RNA molecules (57). 
Steroid receptors can recruit coregulators via their AF-1 and via their AF-2 domain. Because 
of their high LBD sequence similarity MR and GR share many of their AF-2 interacting 
coregulators (which incidentally receive more attention, based on experimental advantages in 
studying the ligand dependent AF-2, rather than the AF-1 which is ligand independent when 
studied in isolation). However, a number of MR-specific coregulators have been reported, 
such as Eleven-nineteen Lysine-rich Leukemia (ELL) and RNA helicase A (RHA) (58, 59). 
AF-2-coregulator interactions are based on the presence of so-called NR-boxes in the 
coregulator protein: amino acid motifs that have an LxxLL sequence at their core. Agonist 
binding to the receptor causes a conformation shift that allows interactions with these NR-
boxes (60). Coregulators may have several NR-boxes, which may lead to interaction with 
multiple nuclear receptors that have different affinities for each NR box. The total number of 
(AF-1 and AF-2) nuclear receptor coregulators is now over 300 (61). One may (crudely) 
estimate that 10 or 20 percent of these may be relevant for MR and/or GR dependent 
transcription, based on screenings for AF-2 interacting coregulators and the predicted higher 
selectivity of the AF-1 coregulators reported in literature. 
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Nuclear receptor-coregulator interactions depend on the amino-acid sequence of their nuclear 
receptor-interaction domain, as well as the presence and activation status (i.e. conformation) 
of other co-expressed steroid receptors and the overall availability of coregulators (62). 
Interestingly, the coregulator repertoire may allow opposite transcriptional effects of 
glucocorticoids on the same gene promoter in different cell types (63). Moreover, increasing 
coactivator availability can reverse the transcriptional repression of one steroid receptor by 
another (57, 64). Finally, in some cases concomitant ligand dependent degradation of nuclear 
receptors and coregulators by the proteasome is important for their transcriptional activity 
(65). This may restrict the availability of coregulators to other nuclear receptors, hence, 
focusing cellular function to specific pathways. Thus, coregulators form a major factor in 
glucocorticoid responsiveness that is, however, far from completely understood. 
Several coregulators are abundantly expressed in the brain, showing wide distribution (66, 
67). These include members of the best studied classes of coregulators, the p160 Steroid 
Receptor Coactivator (SRC) family member SRC-1 (68, 69), CBP/p300 (70, 71) and 
corepressors SMRT and NcoR (66). Others, such as SRC-3 (also a p160 family member), 
seem to be expressed mainly in the hippocampus (68, 72). These coregulators often 
colocalize in cells in relevant brain regions with steroid receptors, presumably able to 
modulate steroid sensitivity, underlining their importance for normal steroid receptor 
functionality (73-75).  
Given the importance of coregulators in setting steroid sensitivity, a number of laboratories 
have studied regulation of coregulator expression in the brain. Factors that alter expression of 
particular coregulators in the brain include sex (76, 77) and age (78, 79), while the regulation 
of SRC-1, NcoR and SMRT by thyroid hormone and estrogen has been reported (66). 
Treatment with testosterone, restraint stress, the time of the day and photoperiod may also 
influence the expression of coregulators (75, 80, 81), as well as elevation of glucocorticoids 
Figure 3. Relation between GR mRNA and protein. The 8 coding exons of the GR gene and the protein 
domains they code for. Exon 2 codes for the N-terminal domain of the protein which contains the major 
transcriptional activation domain τ1. Exons 3 and 4 code for two zinc-finger domains that are involved in 
DNA-binding and homodimerization. Finally exons 5–9 code for the C-terminal end of the protein which 





(82).  However, the majority of these studies investigated the expression of p160 family 
members, and these studies certainly do not keep pace with the speed at which new 
coregulators have been discovered. All in all, there seems to be little compelling evidence to 
suggest that regulation of coregulator expression in the adult brain is a major regulatory event. 
It rather has been argued that post-translational modifications of coregulators could have a 
major impact on their function (83). 
 
SRC-1 
SRC-1 was one of the first coregulators to be discovered (64). It can interact with ligand-
bound steroid receptors, including GR, MR (82), estrogen (ER) and progesterone (PR) 
receptors. It can recruit other coregulators such as CBP/p-300 (84) and possesses HAT activity 
(85). It shows wide expression and distribution in the brain and is transcribed from by the 
NCoA-1 gene which codes for two different splice variants (SRC-1a and SRC-1e). The SRC-
1e mRNA contains an additional exon with an earlier stop codon than SRC-1a (86). Therefore, 
SRC-1e protein is shorter despite the longer SRC-1e mRNA. At the protein level, SRC-1a 
contains four Nuclear Receptor interaction domains (LLXLL motifs or NR boxes) while SRC-
1e contains three. Interestingly, the C-terminal SRC-1a-specific NR box is the one that has the 
highest affinity for GR compared with the central ones (87). The splice variants show 
differential distribution in the brain (69), and in cell lines they have differential effects on 
transcription via MR, GR and ER (88, 89). Regarding adaptation to stress, SRC-1a and 1e 
have opposite activities in relation to the potentiation of GR repression of the crh promoter by 
glucocorticoids (63).  
In vivo, SRC-1 is necessary for GR-dependent gene regulation in the core of the brain stress 
system. Knockout mice show strong GR resistance for the downregulation of both CRH 
mRNA in the hypothalamus, and POMC mRNA in the anterior pituitary (28, 90). Despite this 
rather dramatic transcriptional phenotype, the activity of the HPA-axis is almost normal in 
these mice, even if they tend to have slightly higher stress-induced corticosterone secretion. 
Interestingly, SRC-1 is also involved in CRH expression in the central nucleus of the 
amygdala. Not only do SRC-1 knockout mice lack the upregulation of CRH mRNA in 
response to glucocorticoids, they also show lower basal CRH expression in the central 
amygdala than wild type littermates, suggestive of GR-independent effects of this coregulator 
(28). Conversely, the majority of GR target genes are normally expressed and regulated in 
SRC-1 knockouts. It is still unknown to which extent SRC-1 can influence learning and 
memory and stress reactions as a coregulator of GR. Overexpression of SRC-2 in the lack of 
SRC-1 may be responsible for the lack of behavioral differences between SRC-1 KO and wild 
type animals (91, 92). A more general role of SRC-1 in neuronal function is suggested by a 
delayed development of purkinje cells in the cerebellum of SRC-1 knockout mice, but the 
nuclear receptor that is linked to this phenotype is unknown (72). 
SRC-1 has an important role in sexual behavior and differentiation, as indicated by its 
expression in brain areas relevant for sexual function, coexpression and interactions with ER 
and PR in the brain (73, 93, 94) and the effects of their blockade in such functions. For 
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example, depletion of SRC-1 with oligodeoxynucleotide treatment leads to disruption of 
estrogen- and progesterone-induced sexual behavior in female rats (91). Similarly, inhibition 
of SRC-1 expression by repeated administration of locked nucleic antisense oligonucleotides 
targeting SRC-1 in the hypothalamus-preoptic area of male Japanese quail leads to reduction 
of testosterone-dependent sexual behavior (95). Moreover, antisense oligonucleotide targeting 
of SRC-1 in the hypothalamus could increase lordosis behavior in androgenized female and 
male rats (96). These results underscore involvement of SRC-1 in the signaling of multiple 
nuclear receptor types in the brain. 
 
SGRMs 
Particular neuromodulatory effects that are mediated by NRs such as MR and GR depend on 
specific interactions with downstream proteins. This offers a new level of pharmacological 
modulation of NR function beyond the classical agonists or antagonists as it is possible to 
selectively activate or block particular NR-coregulator interactions, while leaving processes 
that depend on other coregulators unaffected. This principle of selective hormone receptor 
modulators (SHRMs), may lead to the development of ligands that can exert the desired 
experimental or clinical effects, with a minimum of undesired side effects. 
The most prominent type of selective modulation for glucocorticoid signalling has been GR 
ligands that have anti-inflammatory efficacy, but limited effects on metabolism or 
osteoporosis (97, 98). However, also in relation to the brain, it may be beneficial to distinguish 
between different effects of glucocorticoids. For example, blocking detrimental effects of 
chronically elevated glucocorticoid exposure with full antagonists will lead to disinhibition of 
the HPA axis and in this way will counteract efficient antagonism. It is also unlikely that 
blocking all effects of GR on emotional and cognitive processes will be the optimal way to 
counteract negative effects of stress. Lastly, induction in the brain of a pro-inflammatory state 
by pharmacological blockade of GR in astrocytes and/or microglia may not be desirable (99). 
Selective GR (or in fact: MR) modulators may therefore also be beneficial in stress-related 
psychopathology. They most certainly will be useful to dissect the molecular mechanisms of 
glucocorticoid action in experimental settings. 
Originally, it has been tried to base selective GR modulation on the dissociation of effects that 
depend on DNA binding by the receptor, and classical transrepressive effects directly on pro-
inflammatory transcription factors NF-kB and AP-1 (100). The GR ligand ‘Compound A’ is 
an example of this mechanism, as it induces inhibition of NF-κB-dependent pro-inflammatory 
transcription, but is unable to induce DNA binding of GR (101, 102). However, part of the anti
-inflammatory effects mediated by GR do depend on binding by GR to classical GREs (103). 
Coghlan et al. (104) showed a GR ligand that retained anti-inflammatory effects while 
preventing the GR effects on glucose metabolism and impact on bones, and demonstrated that 
the specificity of the compound resulted from the specific GR-coregulator interactions. An 
arylpyrazole-type of GR ligand was reported to have selective agonism with respect to 
induction of decreased hippocampal neurogenesis without affecting skeletal muscle protein 




“ligand 5” was shown to have transcriptional effects on only a small number of target genes in 
cell lines (106). Although its mechanism of action is unknown, ‘ligand 5’ proves the point that 
GR effects relevant for modulation of brain may be quite selectively targeted with selective 
modulator types of drugs.  
Selective receptor modulators for MR have not been studied much, as full MR antagonism has 
been a major clinical goal in cardiovascular disease. However, MR agonism in the brain may 
be of benefit in relation to particular psychiatric disorders, such as depression (107), where its 
expression has been shown to be decreased in several brain areas (108). The development of 
selective MR modulators is currently taking place and it will be exciting to see what the 
potential of such ligands will be (109). 
 
Antisense oligonucleotides 
Antisense oligonucleotides (AONs) (Figure 4) are small pieces of modified RNA or DNA that 
can hybridize to RNA. In this manner they can generate different effects depending on the 
AON chemistry and target site (see Figure 5). Initially, AONs were used to induce gene 
knockdown (110). This can be achieved through RNase H, an ubiquitous enzyme that cleaves 
RNA:RNA or RNA:DNA hybrids (Figure 5a). The AONs used for this application are 
generally modified with a phosphorothioate backbone, which increases AON stability and 
enhances uptake of the AON over cell membranes. Gene knockdown can also be achieved 
using AONs targeting the translation start site (translation block, Figure 5b). Here, AONs can 
be modified further to render them RNase H resistant by addition of a methyl or methoxy-
ethyl group to the 2’O sugar ribose, which is the target cleavage site of the RNase H enzyme. 
Alternatively, nucleotides have been modified even further, e.g. using phosphorodiamidate 
morpholino oligomers (PMOs), peptide nucleic acids or locked nucleic acids. PMOs have 
been used for developmental studies in zebrafish embryos (111, 112). Multiple RNase H 
dependent AONs are in clinical trials including one against high-grade glioma in phase IIb 
(commercial name: trabedersen) (113), and one has even been registered as a drug for 
cytomegalovirus induced retinitis (commercial name: vitravene) (114).  
However, with the availability of shRNA and siRNA, which generally gives a more robust 
gene knockdown (or complete knockout when cre-recombinase systems are used), the use of 
AONs is often not the method of first choice to achieve knockdown (in spite of advantages 
related to cellular uptake - see below). Meanwhile, other AON applications that use different 
mechanisms of action are gaining more interest. The best-known application is the 
manipulation of splicing. Using AONs that target splice sites or exonic/intronic inclusion 
signals located within exons or introns, exons can be hidden from the splicing machinery, 
resulting in the skipping of the target exon (Figure 5c). This can have multiple applications, 
e.g. switching from one isoform to another, skipping an aberrantly introduced exon to restore 
the normal transcript, or introducing an out-of-frame deletion to knock down expression of a 
gene. The latter approach may also be considered as a complementary method to AON-
induced knockout through RNAse H dependent cleavage of RNA:DNA hybrids (115). Exon 
skipping resulting in the expression of truncated, non-functional proteins may be of particular 
17 
 
interest in relation with genes or gene pathways which are considered “undrugable”. Since 
specific ligands or antagonists cannot always target molecules of interest, AON-mediated 
RNA targeting can be a good alternative to achieve partial and/or reversible knockdown of 
such proteins.    
Finally, another application of exon skipping is to reframe transcripts allowing the production 
of an internally deleted, partially functional protein rather than a prematurely truncated non-
functional protein (Figure 5c). This has been extensively studied as a therapeutic approach for 
Duchenne Muscular Dystrophy (DMD). Protein restoration has been shown in patient-derived 
cell cultures and in animal models this led to a rescued phenotype (116-118). After 
encouraging results in phase I and I/II clinical trials (119-123), this approach is currently 
tested in phase III clinical trials. As will be detailed below, this strategy to generate deletion 
variants of proteins bears much promise for experimental neuroscience too. In other cases, 
intron splicing silencers may be targeted, resulting in exon inclusion and therefore increase of 
the expression of a gene or isoform. Here, the most prominent application is rescue of spinal 
muscular atrophy by AON mediated stimulation of the expression of a functional homologue 
(see below) (124-127). 
 
Figure 4. A. Fluorescent image of a mouse brain section stained with hoechst (blue) (10X magnification). 
The white box indicates the location of the central amygdala. B. The white box from picture A in 
magnification. AONs  (green) are colocalized with hoechst in the cellular nuclei (20X magnification).  C. 




Figure 5. Schematic representation of different modes of action of antisense oligonucleotides. A. RNase 
H- dependent pathway. Binding of antisense oligodeoxyribonucleotides (AONs) with a phosphorothioate 
backbone results in a RNA:DNA hybrid, which activates Rnase H. RNaseH will cleave them RNA and 
prevents the translation in to a protein.  B. RNase-independent translational block. 2’ OH modified Rnase 
H-resistant oligomers targeting the translation start site prevent translation and elongation. AONs bind-
ing to the AUG initiation site or downstream prevents binding of the ribosomal units or results in steric 
blockage. C. Alternative splicing. 2’ OH modified RNaseH-resistant or alternatively modified AONs 
complementary to the target pre-mRNA can result in: (1) inclusion of an exon by binding to the exonic 
splicing silencers (ESEs)or intronic splicing silencers (ISSs), (2) exclusion of an exon by binding to the 3 
or 5 slice sites or exon-internal sequences, resulting in an in-frame transcript and translation of a shorter 





A very important aspect of all splicing-modulation or gene-silencing operations is specificity 
to the selected target. siRNAs exert their actions in the cytoplasm via interactions with the 
RNA-induced silencing complex (RISC) in the cytoplasm (128). Off-target effects appear 
when siRNA strands interact with partially complementary regions of mRNAs other than the 
fully complementary target mRNAs (129-131). AONs development has faced the same issues 
in the past (132) and the solutions included modifications of  the backbone to reduce base-pair 
affinity, thus reducing off-target effects (133, 134). Luckily, these modifications can be 
applied to siRNAs as well (132). A problem that might arise is cell death due to oversaturation 
of cellular RNA pathways by siRNAs (135) that are necessary for normal   cellular function. 
However, this problem does not exist with AONs since they exert their activity in the nucleus 
without the need for anything equivalent to the RISC complex (136). 
 
Cellular Delivery 
In all instances of RNA or DNA interference in the brain, delivery is an issue. In vivo 
manipulation of gene expression with shRNA very often depends on the use of viral vectors 
(137-139), as do CRE-recombinase mediated gene excision (26) or gene overexpression 
models (140, 141). However, AONs after reaching the brain, are readily taken up by neurons, 
and are therefore independent of viral transduction of neurons (Figure 4b-c).  
Delivery of viral vectors has been associated with various levels of toxicity in the brain, 
mainly depending on viral type used. For example, AAV vectors have been shown to induce 
neurotoxicity when delivered to the CNS (138, 142-144), although serotypes may differ in 
that aspect (145). Other viral types, such as retrovirus, show milder toxicity, but they are not 
suitable for investigation of long term effects and have limits in the cellular types they can 
infect (146). Lentivirus causes less inflammatory and immune responses, but it still shares the 
disadvantage that pre-existing immunity to the parental wild-type virus may cause an 
accentuated immune response. In contrast, for 2-O’-modified-phosphorothioate AONs only 
very mild toxicity has been reported, which did not interfere with their desirable effects (124, 
147) after delivery in the brain via the ventricles, or in cultured neuronal cells (148). Although 
it has been shown that phosphorothioate AONs and siRNAs can have an immunostimulatory 
effect via toll-like receptors (TLRs) (149, 150), appropriate 2-O’ modifications, such as 2-O’-
methylation can suppress these effects (149, 151, 152). The toxic effects that have been 
reported in some studies after AON delivery in the brain may be due to the vehicle used (153). 
Results from our group showed no immune response to 2-O’-methyl-phosphorothioate AONs 
over saline treatment after a single local injection in the Central nucleus of the Amygdala 
(CeA) of the mouse brain (Chapter 2 of this thesis) (86).  
Compared to viral delivery methods, AONs have a very rapid uptake and initiation of the 
effect (154, 155) (within minutes to hours), which allows for administration between different 
stages of the same experiment (155, 156). Secondly, AONs administration allows better 




e.g. complete or too high levels of knockdown (116, 124, 136). In contrast, virally-mediated 
methods tend to produce an all-or-nothing effect, particularly when cre-recombinase systems 
are used (26, 157). Another characteristic of AON targeting is the possibility to discontinue 
treatment (136).  Although AONs have a longer half-life than, for instance, siRNAs (136), 
eventually they are degraded allowing gene expression to return to basal levels. Viral vectors, 
however, have a virtually permanent action, although long term effects may depend on viral 
type (146). Obviously, in instances where long-term manipulation is the goal, a single 
treatment with a long term effect may be desirable (124). Finally other advantages include 
rapid production and lack of GMO safety related issues, since no genetically engineered 
viruses are involved and there is no risk of recombination or reversion to wild type virus (146, 
158). 
On the other hand, even when methods of virus-independent, direct delivery of siRNA are 
considered, for example based on conjugations (159) several other issues appear. These 
methods are characterized by various inherent challenges, such as high degradation rate of the 
siRNA, low cellular uptake and efficiency (160), and induction of interferon responses (135, 
161, 162). In comparison, AONs have a lower turnover rate (136), more prolonged action 
(130) and, as they are single stranded rather than double stranded, better cellular uptake 
(Chapter 2). 
In conclusion, AON treatments appear as an attractive approach not only in cases where they 
restore protein function (such as DMD) but in many other cases where modulation of gene 
expression is required. Moreover, they offer advantages over other approaches such as siRNA 
interference that may be very advantageous in certain contexts.  
 
Brain Delivery of AONs 
A major challenge of both AON and shRNA applications in neuroscience and in particular for 
possible clinical use in neurodegenerative disorders is the actual delivery to the brain. The 
blood brain barrier (BBB) is a physiological obstruction for molecules to enter the brain and 
molecules can only enter the brain interstitial fluid by transport through the brain capillary 
endothelial cells (163). Intravenous or intraperitoneal administration of phosphorothioate 
oligonucleotides in rodents showed a very low uptake in brain (164, 165). Increased brain 
uptake of AON after peripheral delivery can be achieved by increasing the permeability of the 
BBB (166) or through encapsulating the AON in liposomes conjugated to monoclonal 
antibodies (167, 168). Another way to solve this problem is by local injections in the desired 
brain region if spatial specificity is important or by injection in the cerebrospinal fluid if broad 
distribution in the brain is deemed more important.  
Direct injection in specific brain regions is a method that has been widely used both in rodent 
studies and in human patients (169). Experimentally, they offer insight in local effects of 
widespread factors (170), and can have the advantage of contralateral controls in the same 
animal. Moreover, it provides the options of single injections or repeated/continuous delivery 
via cannulation. Importantly, it also offers the possibility of reducing the injected dose, thus, 
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decreasing potential toxic or immunogenic effects. In human patients intracranial delivery is 
used in the context of glioblastoma treatment with AONs (113). 
The alternative of intraventricular (or intrathecal) delivery into the cerebrospinal fluid has also 
proven successful. Continuous infusion into the ventricle of rodent and nonhuman primate 
brains showed significant concentrations of AON throughout the brain, brain stem and spinal 
cord. Significant reduction of targeted mRNA indicated that the AON is readily taken up by 
cells (136). The advantage of ventricular infusion through a surgically implanted pump is that 
there is constant delivery where the dosage can be accurately regulated (171). Furthermore, the 
disadvantage of the AONs’ restricted ability to cross the BBB also is a clear advantage, since 
after ventricular infusion the AONs will remain in the brain (124) thereby reducing side 
effects on peripheral organs like liver and kidney that readily take up AONs. 
In conclusion, while AONs for use in the CNS cannot be administered systemically, they have 
excellent entry into cells once they passed the BBB. For several backbone chemistries, it has 




The most widely used application of AON-mediated RNA targeting in the CNS has been the 
downregulation of gene expression through intranuclear RNase H-mediated cleavage of 
DNA:RNA hybrids (110, 153) (Figure 4a). Thus, the AON in this case is targeted against an 
mRNA sequence of interest (153). This approach offers an alternative, with certain 
advantages, to knockdown induced by viral vectors and siRNAs which are mediated by the 
RISC complex. We present a few recent examples from which the advantages of ‘classical’ 
knockdown use of AONs is apparent. 
Ma et al., (2011) used AONs to knock down BDNF expression in various brain areas and 
studied its involvement in conditioned taste aversion memory formation (154). They showed 
that BDNF synthesis in the CeA is necessary for the consolidation of long term memory 
formation of conditioned taste aversion. Likewise, AONs have been also used to knock down 
the expression of CRH in the CeA, temporally (155, 156). In a series of experiments targeting 
CRH mRNA it was shown that CRH plays an important role in contextual fear conditioning 
consolidation in the CeA (155). Furthermore, it was shown that CRH involvement in this 
context may be important up to 24 hours after training for successful consolidation of 
contextual fear (156). These studies illustrate the advantage of infusing AONs at different time 
points (154).  
AON-mediated knockdown has been combined with other gene-silencing techniques to serve 
specific experimental purposes, or even to elucidate the mechanisms behind, for instance RNA 
interference. Hemmings-Mieszczak et al. (2003) used mixtures of siRNAs and AONs to 
achieve a higher degree of reduction of the expression of the pain receptor P2X3, in vitro, and a 
more pronounced functional outcome. The effect was stronger when the siRNA and the AON 




complementary sequences (172). 
AONs were recently used in an elegant way to inhibit the expression of proteins associated 
with the RISC complex. AON-mediated downregulation of Argonaute proteins Ago1 and 
Ago2, combined with modified cleavage deficient siRNAs, showed that off-target effects of 
siRNAs are independent from Ago2 cleavage, but they require interaction with Ago proteins 
and the RISC complex (130). A similar approach was used to investigate the involvement of 
the RISC complex in pre-rRNA processing. Targeting of Dicer, Drosha or Ago2 lead to 
impairments in pre-rRNA processing, suggesting a role of these proteins in the biogenesis of 
rRNA (173). The great advantage of AON-mediated knockdown here is that its action depends 
on an entirely different mechanism from siRNA allowing interference with one without 
affecting the other.  
Thus, RNase H-mediated cleavage of DNA:RNA hybrids still is broadly used in basal and 
clinical research. In addition, exon skipping and inclusion offer a number of possibilities that 
are unique for AONs. 
 
Aim of the thesis 
Modulation of sensitivity to glucocorticoids may be of therapeutic interest for 
psychopathology. However, due to the pleiotropic effects of glucocorticoids, a global 
approach such as treatment with GR agonists or antagonists may have serious adverse effects. 
Here we attempted to regulate the sensitivity of discrete GR-dependent pathways to 
glucocorticoids, in relation to stress, using two different approaches:  the first approach we 
used was the local modulation of splicing of SRC-1, a coregulator of the GR, in the CeA and 
the shift of the expression ratio towards the splice variant that represses the CRH promotor; 
the second approach used here, was the targeting of the GR with ligands that may act as 
selective modulators and have differential effects on specific GR-dependent pathways. 
 
Outline of the thesis 
In chapter 2 we investigated the cellular uptake, efficacy and adverse effects of treatment with 
AONs targeting the SRC-1e specific exon in the brain. In chapter 3 we studied the functional 
effects of a shift in the expression ratio of the two isoforms in favour of SRC-1a in the CeA. In 
chapter 4 we tested a novel GR ligand (C108297) with mixed agonist and antagonist 
properties on the regulation of crh expression and the HPA axis, regulation of gene expression 
in the hippocampus and fear memory consolidation. In chapter 5 we used a similar approach to 
test another novel GR ligand (C118335) with mainly agonist properties. In chapter 6 a 
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Antisense-mediated isoform 
switching of Steroid Receptor 
Coactivator-1 in the central nucleus 





Antisense oligonucleotide (AON)-mediated exon skipping is a powerful tool to manipulate 
gene expression. In the present study we investigated the potential of exon skipping by local 
injection in a specific brain nucleus. For proof of principle of feasibility we studied uptake by 
different cell types, translocation to the nucleus and potential immunostimulatory effects at 
different time points after a local injection in the central nucleus of the amygdala (CeA) of the 
mouse brain of a control AON targeting human dystrophin with no targets in the murine brain. 
To evaluate efficacy we targeted the splicing of steroid receptor coactivator-1 (SRC-1), a 
protein involved in nuclear receptor function. This nuclear receptor coregulator exists in two 
splice variants (SRC-1a and SRC-1e) which display differential distribution and opposing 
activities in the brain, and whose mRNAs differ in a single SRC-1e specific exon.  
We found that AONs were taken up by corticotropin releasing hormone expressing neurons 
and other cells in the CeA, and translocated into the cell nucleus. Immune responses after 
AON injection were comparable to those after sterile saline injection. A successful shift of the 
naturally occurring SRC-1a:SRC-1e expression ratio in favor of SRC-1a was observed, 
without changes in total SRC-1 expression.  
We provide a proof of concept for local neuropharmacological use of exon skipping by 
manipulating the expression ratio of the two splice variants of SRC-1, which may be used to 
study nuclear receptor function in specific brain circuits. We established that exon skipping 
after local injection in the brain is a versatile and useful tool for the manipulation of splice 





Alternative splicing in the brain has gained significant attention recently and may be important 
for a vast number of processes [1] such as synaptic function [2] and learning and memory [1]. 
Examples of alternatively spliced genes include the D2 receptor gene [3], the corticotropin 
releasing hormone (CRH) receptor genes [4] and the cannabinoid receptor genes [5, 6]. A 
limitation to the study of the roles of the various splice variants in brain function is that very 
often specific ligands or inhibitors are lacking. Furthermore, transgenic approaches may be 
both costly and time consuming, and/or depend on viral delivery which may induce immune 
responses [7].  
Single stranded DNA or RNA antisense oligonucleotides (AONs) that target RNA transcripts 
can be used to manipulate gene expression in different manners. DNA:RNA or RNA:RNA 
hybrids can be cleaved by RNase H resulting in knockdown of gene expression. A similar 
effect can be achieved via steric hindrance of the ribosomal complex by an AON resulting in 
mRNA translation arrest and blocking of protein expression [8]. A third mechanism involves 
the hybridization of an AON to intronic/exonic inclusion sequences of primary RNA 
transcripts, thus rendering specific exons inaccessible to the splicing machinery and leading to 
skipping of the exon [9]. In a similar fashion, AONs can hybridize to intronic/exonic exon 
exclusion sequences and result in inclusion of target exons [7, 10]. 
 
To date, modulation of splicing by AONs has been used as a potential treatment approach for 
several diseases, including Duchenne muscular dystrophy (DMD) and models of spinal 
muscular atrophy (SMA) [10-12]. Effective protein restoration in DMD via exon skipping has 
been shown in patient derived cell cultures, animal models, (reviewed in [9] and even in 
clinical trials [13, 14]. Similar results have been obtained in SMA via the related mechanism 
of exon inclusion [10, 15-17].  
Despite the potential of splicing modulation, AONs have been used in an experimental setting 
mainly to induce knockdown of gene expression [18-20], while antisense-mediated 
modulation of splicing has not been used widely as a research tool in the brain. One of the 
obstacles preventing their more widespread application in the central nervous system (CNS) is 
their inability to cross the blood-brain-barrier of adult animals [21]. Nevertheless, when AONs 
are applied directly to the CNS via intracerebroventricular (ICV) or intrathecal administration, 
the results show considerable potential [10, 12, 21] and long-lasting effects [10, 21].  
In this study we evaluated the efficacy and occurrence of immune-related side effects after a 
single local AON injection in the central amygdala of the mouse brain. As proof of principle, 
we targeted steroid receptor coactivator-1 (SRC-1), a gene that codes for two splice variants, 
SRC-1a and SRC-1e, which only differ in one exon (Figure 1; [22, 23]). SRC-1 can act as a 
coregulator of glucocorticoid receptor (GR) dependent transcription [24], as well as of other 
nuclear receptors [25]. The SRC-1 splice variants show differential activity and distribution in 
the brain [26]. The splice variants have been shown to exert opposite effects on the GR-




We targeted exon 22 of the SRC-1 gene (Figure 1) using AONs, examined their cellular uptake 
by different cell types, exon skipping efficacy over time and potential immunostimulatory 
effects. For cellular uptake and potential immunostimulatory effects we used an AON 
targeting human dystrophin that has no known targets in the murine genome, in order to 
investigate the target-independent physico-chemical properties of 2-O’-methyl modified 
phosphorothioate oligonucleotides. Our results showed adequate uptake by cells in the CeA 
and translocation into the cell nucleus, combined with detectable isoform switching until at 
least 7 days after a single injection and a practically complete lack of immunostimulatory 
effects compared with vehicle injection. 
Figure 1. Schematic representation of the mRNA of the two SRC-1 splice variants. Boxes represent ex-
ons and thicker full lines represent introns. Dashed lines indicate possible splicing events. The approxi-
mate position of stop codons is also marked. If exon 22 is included, SRC-1e is expressed. Exon 22 con-
tains an earlier stop codon, therefore SRC-1e protein is shorter than SRC-1a. AONs targeting exon 22 
can render it inaccessible to the splicing machinery and therefore, shift the expression of SRC-1 towards 





Animals, stereotactic surgery and tissue processing: C57bl/6j male mice between the ages 
of 12-14 weeks (Janvier SAS, France) were used for all experiments. Animals were singly 
housed in individually ventilated cages at a 12 hour light cycle with lights on at 7 am. Food 
and water were available ad libitum. All animal experiments were carried out in accordance 
with European Communities Council Directive 86/609/EEC and the Dutch law on animal 
experiments and were approved by the Leiden University animal ethical committee (protocol 
number: 10128). Animals were anesthetized with a cocktail of Hypnorm-Dormicum-
demineralized water in a volume ratio of 1.33:1:3. The depth of anesthesia was always 
confirmed by examining the paw and tail reflexes. When mice were deeply anesthetized they 
were mounted on a Kopf stereotact (David Kopf instruments, Tujunga, CA, USA). For every 
experiment, animals were bilaterally injected with 0.5 μl of the appropriate solution (sterile 
saline, AONs at a concentration of 400 pmol/μl in sterile saline (Eurogentec, Liège, Belgium)) 
in the central amygdala (coordinates relative to bregma: -1.25 mm anterior-posterior, ±2.95 
mm medio-lateral and -4.75 mm dorso-ventral) [50]. For injections, customized borosilicate 
glass micro-capillary tips of approximately 100 μm in diameter, connected to a Hamilton 
needle (5 μl, 30 gauge) were used. The Hamilton syringe was connected to an injection pump 
(Harvard apparatus, Holliston, MA, USA) which controlled the injection rate set at 0.15 μl/
min. After surgery the animals were returned to the home cage and remained undisturbed until 
sacrifice, with the exception of daily weighing in order to monitor their recovery from surgery. 
To assess mRNA expression, animals were decapitated after an intraperitoneal injection (i.p.) 
of overdose Euthasol (ASTfarma, Oudewater, the Netherlands), brains were removed quickly 
and snap frozen on dry ice. For detection of the presence of AONs over time and putative 
immunostimulatory effects, mice were sacrificed with transcardial perfusion with a solution of 
4% paraformaldehyde (PFA) (Sigma-Aldrich, Zwijndrecht, the Netherlands) in 0.1 M 
phosphate buffer saline (PBS)  after an i.p. injection of overdose Euthasol, 1, 3, 5, 7 and 14 
days after the injection. Each time point contained 3-7 animals. In order to assess potential 
immunostimulatory effects we used animals injected with 0.5 μl sterile saline (vehicle) that 
were sacrificed either 3 or 7 days (4 per group) after the injection as controls for the respective 
time points. Three additional animals were sacrificed without having been operated on. After 
sacrificing the animals, the brains were removed and postfixated overnight in 4% PFA at 4oC. 
Subsequently they were cryoprotected in 15% and 30% sucrose, snap frozen on dry ice and 
stored at -80oC. 
Antisense oligonucleotides: Two different green fluorophore labeled AONs were used: one 
targeting human dystrophin, which has no known targets in the mouse 
(CGCCGCCAUUUCUCAACAG), labeled with a fluorescein amidite (FAM) fluorophore and 
one targeting exon 22 of SRC-1, that is specific for the SRC-1e splice variant 
(CUGUAGUCACCACAGAGAAG), labeled with Alexa Fluor® 488 . The AON against exon 
22 of SRC-1e was administered in order to investigate whether it can induce exon skipping, 




potential immunostimulatory effects. AONs were modified with a full-length 
phosphorothioate backbone which increases AON stability and cellular uptake and consisted 
of 2-O’-methyl RNA to render them RNase H resistant and to counterbalance potential 
immunostimulatory effects caused by the phosphorothioate modified backbone [34, 35, 51, 
52]. 
Immunofluorescence:Brains were sectioned at a thickness of 25 μm on a Leica cryostat and 
sections stored in antifreeze solution [30% ethylene glycol (Merck, Darmstadt, Germany), 
20% glycerol (Sigma-Aldrich), 0.02 M Na2HPO4 (Merck), 6.6 mM NaH2PO4 (merck)] at -
20oC until use. Before use sections were washed in PBS to remove anti-freeze. Subsequently 
sections were incubated in 0.5% triton X-100 (Sigma-Aldrich) in PBS for 30 min to increase 
permeability of the cells and washed with PBS. Blocking with 2% normal donkey serum 
(Brunschwig Chemie, Amsterdam, the Netherlands) in PBS-BTSA for 45 min was followed by 
an overnight incubation with primary antibody at room temperature (table 2). Afterwards, the 
primary antibody was washed out with PBS and incubation with the secondary antibody (table 
2) followed for 2.5-3 h. The secondary antibody was washed followed by 10 min incubation 
with Hoechst (1:10000) (Hoechst 33258, pentahydrate, bis-benzymide, Invitrogen, Breda, the 
Netherlands) and another PBS washing step. Finally, the sections were mounted on glass 
slides, dried and coverslipped with Aqua Polymount (Polysciences Inc, Eppelheim, Germany). 
Slides were stored at 4oC until observation. 
Microscopy: Confocal imaging was performed on a Nikon Eclipse TE 200-E microscope. 
Confocal images were collected as z-stacks at a magnification of 200 or 600 times with a z 
Primary antibodies Secondary antibodies 


































































Table 1. Antibodies and dilutions used for all immunofluorescent stainings. The fluorophore of 
all secondary antibodies was Alexa Fluor® 594  
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step size of 0.5 μm and an image size of 1024×1024 pixels. When two or more markers were 
determined in a single section, the different channels were imaged separately to avoid artifacts 
due to overlap of the emission wavelengths of the fluorescent labels. The same settings were 
used to obtain images for quantification (e.g. at different time points, between subjects or 
between groups for the same marker). Z-stacks were converted to .avi format and then stored 
as single image .tiff files using the z-projection function of Image J (NIH, Bethesda, MD) with 
standard deviation as projection type. Images of damaged sections or images with artifacts 
were excluded from further analysis. Finally, to examine cellular uptake and colocalization of 
different markers we merged different channels of the same image in Image J. 
Image processing: Appropriate thresholds were applied to correct for background. For each 
marker the positive stained area was presented as a percentage of the total area of the visual 
field. In order to reduce measurement bias, holes or ruptures in the tissue were not taken into 
account for the calculation of total area. For determination of immune responses 3-4 pictures 
were used per brain and the mean value of those was used as the sample value.    
Diffusion of the AONs: For determination of the diffusion of the AONs in brain we measured 
the diffusion of the green fluorescence in the medio-lateral axis and the dorso-ventral axis in 
Image J on 4 or 5 10 μm-thick sections per brain (n=6) which were taken 80 μm apart from 
each other. Images were taken on a Nikon eclipse 6800 fluorescent microscope at 100X 
magnification. Before measurements, appropriate background correction was applied. Lines 
were drawn along the medio-lateral and dorso-ventral axes and their length was measured in 
pixels. With help of a calibration slide we converted the values from pixels to μm. The 
positive area for green fluorescence was also measured and total positive volume was 
calculated according to Cavalieri’s rule. Mean and maximum diffusion  distances were 
calculated as well as total volume per sample. 
Laser microdissection and RNA processing: Cryosections at a thickness of 10 μm were 
taken from snap frozen brains and mounted on polyethylene naphthalate membrane slides 
(Carl Zeiss, Munich, Germany). Up to 5 sections were mounted on a slide with adjacent 
sections being on different slides. The slides were stored at -80oC until laser microdissection. 
Laser microdissection was carried out on a Palm laser microdissection microscope as has been 
described elsewhere [53, 54]. Briefly, sections were observed under fluorescent light in order 
to determine regions that had taken up AONs. With the assistance of appropriate software the 
desired regions were selected, microdissected and collected in adhesive caps (Carl Zeiss). 
Collected tissue was then stored in Trizol (Invitrogen) at 4oC until RNA isolation, which was 
always carried out the same day as laser microdissection in order to preserve RNA quality. 
RNA isolation was performed as has been described elsewhere [55]. Briefly, RNA was 
isolated with chloroform and precipitated with isopropanol and linear acrylamide. RNA pellets 
were rinsed with ice cold ethanol 75%, air-dried and resuspended with RNase-free DEPC-
treated demineralized water. Quality and concentration of RNA samples were measured on a 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) using the RNA 600 Pico 
LabChip according to the manufacturer’s instructions.  




potential genomic DNA contamination. Subsequently, RNA samples were reverse transcribed 
with iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Briefly, 4 μl of 5 times iS-
cript reaction mix, 1 μl of iScript reverse transcriptase and 5 μl of Nuclease-free H2O were 
added to 10 μl of DNase I treated RNA. Subsequently samples were incubated for 5 min at 
25oC followed by 30 min at 40oC and finally 5 min at 85oC in a PTC-200 DNA engine cycler 
(Bio-Rad). 
qPCR: Quantitative polymerase chain reaction (qPCR) was performed for assessment of gene 
expression in the CeA of AON injected mice. A 1:1 dilution of cDNA in autoclaved deminer-
alized water was used for qPCR. The quantification of cDNA was performed on a LightCycler 
2.0 (Roche Applied Science, Basel, Switzerland) using LC FastStartDNA MasterPLUS SYBR 
Green I (Roche). 2.5 μl of cDNA was added to a mix of 2 μl 5 times Sybr green mix, 1 μl of 
both forward and reverse primers (5 μM) and 3.5 μl nuclease-free water, in LightCycler Capil-
laries (20 μl, Roche). All measurements were performed in duplicate. The PCR program com-
prised 10 min at 95oC followed by 45 cycles of denaturation at 95°C for 10 sec, annealing at 
60°C for 10 sec and elongation at 72°C for 10 sec, with a subsequent dissociation stage (from 
65°C to 95°C, at a rate of 0.1°C/sec). The SRC-1 splice variants were quantified as an expres-
sion ratio of SRC-1a/SRC-1e; the expression of total SRC-1 and GR was normalized against β
-actin. Quantification of relative expression was calculated using the Pfaffl method [56] and 
normalized against the control group (dystrophin AON). The forward and reverse primers 
used for the different genes were respectively: 5’-CCTCTACTGCAACCAGCTCTCGTC-3’ 
and 5’-TGCTGCACCTGCTGGTTTCCAT-3’ for SRC-1a; 5’-
TGCAACCAGCTCTCGTCCACTG-3’ and 5’-GCTCCTCTAGTCTGTAGTCACCACA-3’ 
for SRC-1e; 5’-CGACCGCAGAGCAGCAGTTA-3’ and 5’-
GCCGCTCAGTCAGAGAGCTG-3’ for total SRC-1; 5’-CCCTCCCATCTAACCATCCT-3’ 
and 5’-ACATAAGCGCCACCTTTCTG-3’ for GR;  5’-TTTCCCACAGCAGTACGCAT-
3’and 5’-TAATTTGGCCGCTGTCCCAT-3’ for SRC-2 5’-CAACGAGCGGTTCCGATG-3’ 
and 5’-GCCACAGGATTCCATACCCA-3’ for β-actin.  
Statistical analysis: For comparisons between two groups an independent t-test was used. For 
comparisons among multiple groups one-way ANOVA was used followed by Tukey’s post-
hoc test (for comparison of immunostimulatory effects between all groups) or Dunnett’s post-
hoc test (for comparison of fluorescence intensity at different time points with fluorescence 




Cellular uptake: In order to investigate the cell types and intracellular destination of 2-O’-
Methyl phosphorothioate AONs we performed immunofluorescent detection of CRH (which is 
expressed in the CeA), NeuN and Hoechst after local injection of an AON targeting human 
dystrophin, which has no known targets in the mouse. Our results showed that fluorescently 
labeled AONs were taken up by neurons in general, as well as neurons expressing CRH in the 
CeA, and  also  translocated into  the  cell  nucleus (Figure 2A-D).  Quantification showed that  
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Figure 2.  AON uptake by different cell types and nuclear localization in the central amygdala (CeA). A. 
Uptake of AONs by neurons. The green fluorescence of the labeled AONs is colocalized with NeuN 
(red), a marker of neurons. Scale bar 50 μm B. Uptake of AONs by cells expressing CRH. AONs (green) 
are located in the nuclei of those cells (white arrowheads), surrounded by CRH in the cytoplasm (red). 
Scale bar 15 μm. C, D. Localization of AONs (green) in the cell nucleus, colocalized with the nuclear 
marker Hoechst (blue). Scale bar 50 μm. The area within the red square is magnified in D (scale bar 15 
μm). E. Fluorescent intensity in the cell nuclei after an injection of AONs. Fluorescence on day 1 was 
normalized to 100%. One-way ANOVA (F(4,14)= 7.845, p<0.01) followed by Dunnett’s post hoc test (all 
groups compared to the 1 day group) showed a significant decrease of fluorescence after 7 and 14 days 
(Dunnett’s test p<0.05 in both cases). Between the 7- and 14-day groups there was no further decrease. 
F. Uptake of AONs (green) by GFAP (red) positive astrocytes. Several astrocytes have taken up AONs 
while others have not. White arrowheads indicate a few examples of astrocytes that took up AONs 




Table 2. Diffusion of the AONs in the brain in the mediolateral, dorsoventral and anterior-posterior axes. 
Lengths in μm, volumes in mm3. Data shown as mean ± SEM 
Immunostimulatory effects: We analyzed two different markers for microglia activation (CD
-45 and IBA1) and one marker for astrocytes (GFAP). CD-45 is a marker of activated 
microglia, whereas IBA-1 is a constitutive marker of microglia [28, 29]. We compared AON-
injected (with an AON targeting human dystrophin) to saline-injected animals 3 and 7 days 
after the injections. Moreover, we included an untreated group of animals to assess the effects 
of the injections. No differences were observed between saline and AON treated animals at 
either time point (Figure 3-4). AON uptake was also observed in a subset of GFAP positive 
astrocytes (Figure 2F). Little or no uptake by microglia was observed. 
67.5% ± 2.6 of the cells that had taken up the AONs was NeuN positive. This indicates that 
the AONs can indeed be taken up by neurons in the brain and translocate to the nucleus where 
splicing events take place.  
AON detection: In order to determine the stability of AONs in the brain after local injection 
we measured the intensity of the green fluorescence originating from the fluorophore 
conjugated to AONs in the brains of animals sacrificed 1, 3, 5, 7 and 14 days after a single 
injection with an AON targeting human dystrophin. Fluorescence intensity did not differ 
significantly between 1 and 3 days but subsequently decreased over time to less than 50% in 7 
days (Figure 2E). After 7 days, fluorescence intensity remained stable until the last detection 
time point, 14 days post-injection. In these calculations only green signal colocalized with 
Hoechst (cell nuclei) was taken into account, thus restricting our analysis to a functionally 
relevant subcellular compartment.  
Diffusion of AONs: In order to investigate the specific targeting of a selected brain region we 
measured the diffusion of the AONs around the injection site. Our results indicated a well 
localized targeting of about 0.1 mm3 (table 2). 
Measurement Size SEM 
Mean mediolateral diffusion 505 70 
Mean dorsoventral diffusion 671 84 
Mean anterior-posterior diffusion 350 34 
Maximum mediolateral diffusion 903 - 
Maximum dorsoventral diffusion 1015 - 
Mean Volume 0.11 0.03 
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Figure 3. GFAP immunoreactivity 3 or 7 days after a single injection in the CeA. A. 3 days after a single 
saline injection. B. 7 days after a single saline injection. C. 3 days after a single injection of AONs. D. 7 
days after a single injection of AONs. E. GFAP immunoreactivity in the CeA of an untreated mouse. F. 
Quantification of GFAP immunoreactive area shown as percentage of the total area of visual field. One-
way ANOVA followed by Tukey’s post hoc test revealed no significant differences between the 
respective AON and saline injected animals (one-way ANOVA F(4,17)=1.266, p>0.32, N=3-7 animals per 
group). In conclusion, a single AON injection did not induce stronger astrocytosis than saline. Scale bar 




Figure 4. CD-45 immunoreactivity 3 or 7 days after a single injection in the CeA. A. 3 days after a single 
saline injection. B. 7 days after a single saline injection. C. 3 days after a single injection of AONs. D. 7 
days after a single injection of AONs. E. CD-45 immunoreactivity in the CeA of an untreated mouse. F. 
Quantification of CD-45 immunoreactive area shown as percentage of the total area of visual field. One-
way ANOVA followed by Tukey’s post hoc test revealed no significant differences between the 
respective AON and saline injected animals (one-way ANOVA F(4,17)=1.092, p>0.39, N=3-7 animals per 
group). Quantification of IBA-1 immunoreactive area had similar results (one-way ANOVA F(4,17)
=1.535, p>0.23, data not shown). In conclusion, a single AON injection did not induce stronger microglia 
activation than saline. Scale bar 50 μm. Red: CD-45, blue: Hoechst. Green signal (AONs) has been 
omitted for clarity. 
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Isoform switching: In order to determine the efficacy of AONs treatment on exon skipping in 
the brain we used qPCR analysis to measure the expression ratio of the two isoforms in the 
CeA, 3 and 7 days after a single injection with either an AON against SRC-1e or a control-
AON. Three days after the injection the SRC-1a:SRC-1e ratio showed a 2-fold shift in favor of 
SRC-1a in the group injected with AONs against SRC-1e, in comparison to the control-AON 
injected group. However, total SRC-1 expression was not different between the groups (Figure 
5). Seven days after injection the expression ratio was still significantly higher in the animals 
injected with AONs against SRC-1e (approximately 1.5-fold higher than their control injected 
counterparts) without a difference in total SRC-1 expression. As an additional control for 
specificity, mRNA for GR (which may be one of the target nuclear receptors of SRC-1) was 
not significantly different between the groups either at the 3- or the 7-days time point. In view 
of previously reported upregulation of SRC-2 in SRC-1 knockout mice (Xu, 1998), we 
determined SRC-2 mRNA. We did not find a significant difference between the two groups 
regarding SRC-2 expression 3 days post injection. SRC-2 expression was 0.7 ± 0.2 for animals 
injected with AONs targeting SRC-1e and 1.0 ± 0.3 for animals injected with human 




In this study, we investigated the efficacy in AON-mediated isoform switching, AON uptake 
by different cellular types and the putative immunostimulatory effects of AONs, in order to 
evaluate their potential use as a tool in experimental brain research. 
Our results showed that it is possible to alter the expression ratio of the two SRC-1 isoforms 
with a single injection of AONs targeting exon 22 of the transcript of SRC-1e. Three days 
after the injection the isoform expression ratio showed a 2-fold increase in favor of SRC-1a, 
whereas 7 days after a single injection of AONs the respective difference was approximately 
1.5-fold in favor of SRC-1a. In order to confirm that this was a genuine effect and was not 
influenced by downregulation of total SRC-1 we also investigated total SRC-1 expression in 
the two groups, which was shown to be comparable and not significantly different at both time 
points. We also investigated the expression of GR to control for possible differences as a 
consequence of off-target non-homologous binding of the AONs. We selected GR as an 
additional control, because SRC-1 is involved in GR-dependent pathways. Our results showed 
that GR mRNA expression is not significantly different between animals injected with either 
an AON targeting SRC-1e or a control AON 3 or 7 days after a single injection. This finding 
indicates no difference in non-homologous targeting between the specifically targeted and the 
control AONs and is also relevant for future experiments attempting to unravel the role of 
SRC-1 and its isoforms in GR dependent pathways as any effects can be attributed solely to 
SRC-1 isoform switching. Since SRC-2 has been shown to be upregulated in the absence of 
SRC-1 during development [30], we investigated its expression 3 days after injection in order 
to rule out an effect of SRC-1 isoform switching on SRC-2 expression. We did not find SRC-2 
upregulation, which is in line with the absence of effects on total SRC-1. Although a larger- 




Figure 5. qPCR analysis of gene expression 3 or 7 days after a single injection. A. Relative expression of 
the SRC-1a/SRC-1e 3 days after a single injection of AONs. AON treatment targeting exon 22 of SRC-
1e leads to a 2-fold difference of the expression ratio of the two isoforms in favour of SRC-1a 
(independent t-test, t(6)=2.414, p<0.05, n=6-7 per group). B. Relative expression of the SRC-1a/SRC-1e 7 
days after a single injection of AONs. AON treatment targeting exon 22 of SRC-1e lead to 1.5-fold 
difference of the expression ratio of the two isoforms in favour of SRC-1a (independent t-test t(8)=2.420, 
p<0.05, n=5 per group). C, D. Treatment with AON targeting exon-22 of SRC-1e had no effect on total 
SRC-1 expression compared to control 3 (C) or 7 days (D) after a single injection (independent t-tests, t
(11)=0.006, p>0.99 and t(7)=1.304, p>0.57 respectively, n=4-7 per group). E, F. GR expression remained 
unchanged between animals injected with AON targeting exon 22 of SRC-1e and controls 3 (E) or 7 




off-target effects of the AONs used in this study [31], our results from total SRC-1, SRC-2 and 
GR mRNA expression indicate high specificity. In addition, since AONs do not obligatorily 
interfere with endogenous pathways unlike siRNAs they cannot saturate the cellular miRNA 
machinery [21], thus avoiding a source of off-target effects. 
Regarding the effect size of the AONs’ efficacy, it is important to note that the dissected area, 
particularly at longer distances from the injection site may contain cells that did not take up 
AONs. For the group treated with AONs against SRC-1e that would mean a dilution of the 
effect. Therefore, the actual efficacy of exon skipping could well be higher than observed.  
The detection of isoform switching 7 days after a single injection of AONs allows animals 
sufficient time for post-operational recovery and performance of additional experiments, for 
instance, behavioral experiments. In addition, we were able to detect fluorescence of AONs up 
to 14 days after injection, which is probably accompanied by isoform switching to some 
extent, although the decrease of the expression ratio of the two isoforms between 3 and 7 days 
indicates that the effect size may decrease over time. If longer lasting effects are required, 
potential solutions may involve higher doses and repeated or continuous administration [21]. 
Persisting effects have been shown even 6 months after termination of continuous infusion of 
AONs for 7 days in the ventricles of the brain [10], and even single administration may have 
long-lasting effects [32]. 
Astrocytosis and microglia activation may confound any findings in relation to brain function. 
We found no differences in the immune responses caused by a single injection of AONs or a 
single injection of sterile saline 3 or 7 days after the injections. The time course of astrocytosis 
and microgliosis that we observed both in vehicle and AON treated animals was similar to 
what has been previously reported for saline injections [29]. It is unlikely we have reached a 
plateau in immune responses with saline, since it has been shown in the past that 
administration of lipopolysaccharide causes substantially stronger immune responses than 
saline [29] and particularly upregulation of CD-45. Immunostimulatory effects that have been 
observed in other studies may have been caused by the vehicle used [33], or immune 
responses elicited by simulation of Toll-Like receptors (TLRs) through the phosphorothioate 
backbone of the AONs [34]. However, 2-O’-modifications may act as TLR antagonists [35], 
which may account for the lack of immune responses in our study (in spite of the high local 
concentrations of AONs), as well as in others [21]. Hua et al., 2010 reported an upregulation 
of IBA-1 mRNA expression after continuous infusion for 9 days of 2-O’-Methyl modified 
AONs but not of 2-O’-Methoxyethyl AONs compared to saline. This discrepancy between the 
current study and the study of Hua et al. may be due to the different experimental setup. The 
current study used a local single injection of ~1 μg of AONs instead of a continuous ICV 
administration of 10 μg or more per day for 9 days that induced significant upregulation of 
IBA-1 in the spinal cord, or 30 μg or more that was necessary to induce significant 
upregulation of IBA-1 in the brain. Administration of 10 μg of AONs per day was not enough 
to cause significant IBA-1 upregulation in the brain. Although it is difficult to compare final 
local concentrations of the two approaches, our results show that we probably remain well 
within the “safe” range regarding the induction of immune responses. Nevertheless, this 




delivery of treatment and one should be aware of potential risks [7]. 
Before AONs can exert their effect, it is crucial that they cross the cell membrane and the 
nuclear membrane, since splicing takes place in the nucleus [36]. How AONs are taken up and 
how they are transported to the nucleus is not known. It has been shown in models of DMD 
that because of the lack of dystrophin protein, affected muscle cells can more easily take up 
AONs due to the altered properties of their muscle fiber membranes and a more open 
endothelium [37]. However, mechanisms of AON uptake by intact neurons in the CNS are 
probably different and may involve utilization of trafficking pathways for cellular uptake of 
AONs including absorptive endocytosis, pinocytosis and clathrin-, caveolin-, actin-, dynamin- 
dependent and -independent pathways [36, 38-40]. Moreover, AON cellular uptake may 
exploit the natural pathways of cell-to-cell nucleic acid transportation that may be also 
involved in micro-RNA transportation [41]. It is very likely that different physical and 
chemical properties of AONs depending on their chemistry, 2-O’-modifications and length 
may also be determining factors for the manner and efficiency of uptake [42]. The AON 
chemistry used in the current study has been shown to be advantageous for nuclear uptake 
[43].  
We also showed that cells of interest in the CeA can take up AONs; NeuN and CRH positive 
cells represent neurons and cells expressing CRH, a hormone crucial for fear conditioning and 
orchestration of stress responses in the brain [44], and a putative target of SRC-1 mediated 
regulation [45]. NeuN positive cells account for the majority of cells taking up AONs. 
Moreover, we observed sporadic AON uptake by astrocytes and little or no by microglia. The 
low uptake by microglia cells may be due to either the properties of those cells, or the fact that 
they seem to arrive at the injection site probably after AONs have been already taken up by 
other cells. The fraction of AON-positive astrocytes was substantially lower than for NeuN-
positive cells. Other studies suggested that in primates AON uptake by astrocytes may be 
more substantial [21]. On the other hand, GFAP staining visualizes only part of the total 
population of astrocytes [46] since some astrocytes do not express GFAP [47]. Hence, it is 
possible that GFAP negative astrocytes may have taken up AONs. To summarize, based on 
our findings we can conclude that generally neurons in the brain take up AONs, without, 
however, being able to rule out the possibility that different populations of neurons may 
display uptake at different rates, efficiencies or even complete lack of AON uptake. In the 
injected areas in the CeA, though, the vast majority of NeuN positive cells take up AONs. 
It is important to mention that we did not detect the AONs directly, but rather the fluorophore 
with which they were labeled. Since this can be cleaved off, it would be possible that we 
detected fluorophores that were not bound to the AONs. However, that is not likely since 
uptake takes place very rapidly after injections, when little or no degradation of the AON-
fluorophore complex is expected. Moreover, the considerable effect on exon skipping 3 and 7 
days after an injection indicates AON activity which coincides with detection of fluorescence 
in the cells. For this study we made the assumption of equal stability between the two AONs. 
Although the addition of a fluorophore increases hydrophobicity, hence cellular trafficking, it 
also increases its size. Therefore, the diffusion we observe here might be an over- or an 
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underestimation of what it would be without the fluorophore attached. Importantly, efficacy 
has been shown to be similar between labeled and unlabeled AONs [48][49]. Finally, our 
measurements of the diffusion of the AONs indicate that a specific brain region can be targeted 
with minimal leakage to adjacent areas. The diffusion observed here is likely a function of the 
targeted area, the volume and AON concentration and the injection rate and it may not be 
possible to directly extrapolate to other situations. Nevertheless, one would assume that with 
an optimal combination of volume and concentration smaller regions may also be targeted with 
reasonable specificity. 
In conclusion, we have shown that it is possible to induce specific exon skipping and 
subsequent isoform switching of SRC-1 in the CeA without noticeable adverse effects. Our 
future work will address the functional consequences of SRC-1 isoform switching, as well as 
the many additional genes that are potential targets of such. This use of isoform switching with 
AONs has great potential that it must be considered not only in cases where it can restore 
aberrant gene expression and function, but also as an important molecular tool for 
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In preparation 
Steroid Receptor Coactivator-1 isoform 
switching in the central amygdala results 
in impaired contextual fear conditioning 
and abrogation of CRH expression 





Steroid receptor coactivator 1 (SRC-1) is a coregulator of the glucocorticoid receptor (GR) 
involved in the regulation of basal expression of corticotropin releasing hormone (CRH) and 
modulation of CRH expression by glucocorticoids in the brain. The two isoforms, SRC-1a and 
SRC-1e are generated by the NCoA1 gene. SRC-1a lacks an SRC-1e specific exon. The two 
isoforms differ in their activities and distribution in the brain: SRC-1a is more abundant in the 
paraventricular nucleus of the hypothalamus and can potentiate repression at the crh promoter, 
whereas SRC-1e is more abundant in the central amygdala (CeA) and lacks repressive 
capacity. We hypothesized that shifting the SRC-1a:SRC-1e expression ratio in the CeA in 
favour of SRC-1a, using “exon skipping” would decrease the sensitivity of the CeA to 
glucocorticoids and therefore block the glucocorticoid-induced upregulation of CRH 
expression.  
We injected stereotactically in the CeA of mice antisense oligonucleotides, which were 
designed to exclude the SRC-1e specific exon from the mRNA. Subsequently, we tested 
contextual- and cue-fear memory performance, anxiety responses and regulation of CRH 
expression by glucocorticoids in the CeA.  
Our results showed in the CeA a shift of the SRC-1a:SRC-1e expression ratio in favour of 
SRC-1a that led to impaired consolidation of conditioned fear memory, enhanced locomotor 
activity in the open field test and abrogation of the glucocorticoid-induced upregulation of 
CRH expression in the CeA. In conclusion, our findings demonstrate that manipulation of GR 






The ability to orchestrate appropriate adaptive responses to stressors is indispensable for 
survival. The Hypothalamic-Pituitary-Adrenal (HPA) axis plays a pivotal role in the 
orchestration of adaptive responses. Corticotropin releasing hormone (CRH) has a key role in 
the regulation of the HPA axis, as its secretion from the paraventricular nucleus of the 
hypothalamus (PVN) along with other secretagogues to the pituitary stimulates the release of 
adrenocorticotropin hormone (ACTH) (1, 2). ACTH is then released into the systemic blood 
flow, reaches the adrenals and stimulates the production of glucocorticoids, which feedback on 
the brain to suppress the expression of CRH in the PVN. Another important CRH production 
site is the central nucleus of the amygdala (CeA), where the peptide organizes autonomic and 
behavioral responses to stress and is involved in fear and anxiety (3-5). A major modulator of 
CRH expression at both brain sites is the glucocorticoid receptor (GR). The GR is a 
transcription factor mediates effects of glucocorticoids on cognitive processes (e.g. memory 
consolidation), emotional state (e.g. fear responses) and endocrine regulation (5-7). 
Glucocorticoids regulate CRH expression in a distinct brain region-dependent manner: 
treatment with glucocorticoids results in CRH upregulation in the CeA (which may potentiate 
fear responses), but in downregulation in the PVN, as part of the negative feedback loop of the 
HPA axis (8).  
The CeA is an important brain region for emotional responses such as anxiety and acquisition, 
consolidation and expression of conditioned fear (2, 9-11). Its function in both contextual and 
cue fear conditioning has been well characterized and appears to be dependent on GR and 
CRH expression (5). Animals conditionally lacking GR expression in the central amygdala 
have impairments in consolidation of conditioned fear, which can be rescued by post-training 
intracerebroventricular injection of CRH (5). On the other hand, increased CRH expression in 
the CeA may also enhance the reactivity of the HPA axis, particularly during chronic stress 
conditions (12, 13). High CRH expression may result in increased anxiety and depressive-like 
features (12, 14, 15) and may be related to psychopathology (4). The opposite direction of 
glucocorticoid effects on CRH in PVN and CeA illustrates the way in which these hormones 
act at these different sites to promote adaptation to stressors. However, these opposite effects 
also imply that additional factors are involved in the GR-mediated regulation of CRH 
expression (16).  
Nuclear Receptor Coregulators are such additional proteins that are involved in steroid 
regulation of gene expression. Their mode of action involves binding to nuclear receptors and 
recruitment of other transcription factors, stabilization of the transcriptional machinery and 
histone acetylation either via intrinsic histone acetyltransferase activity or by recruitment of 
histone acetylransferases (17, 18). Most coregulators interact with multiple nuclear receptors 
and all nuclear receptors interact with multiple coregulators. This promiscuity of nuclear 
receptors and coregulators offers the aforementioned additional level of regulation of target 
gene expression. 




interact with a.o the GR, the mineralocorticoid receptor (MR), the androgen receptor and the 
estrogen receptor (19-22). SRC-1 knockout mice display impairments in regulation of the crh 
gene in the CeA and PVN by glucocorticoids (23). The SRC-1 gene encodes two splice 
variants, SRC-1a and SRC-1e, which have different expression patterns in the brain and 
opposite activities on the crh promoter (24-26). SRC-1e mRNA contains an extra exon, which 
has an early stop codon (Chapter 2 Figure 1). Hence, while SRC-1e mRNA is longer than SRC
-1a, the SRC-1a protein is larger and presents an additional nuclear receptor binding domain 
(NR box). Hence, the SRC-1a protein contains four NR boxes, three of which are common 
between SRC-1a and SRC-1e and one specific NR box (NR box IV). SRC-1a is abundantly 
expressed in the PVN and can repress the crh promoter, whereas SRC-1e is highly expressed 
in the CeA and lacks repressive activity at the crh promoter in vitro. The functional 
significance of SRC-1 splice variants has not been clarified in vivo. 
Antisense oligonucleotide (AON)- mediated exon skipping is a powerful and versatile 
technique to manipulate mRNA splicing (27). Previously (28), we have shown that a single 
injection of AONs targeting SRC-1 can induce a shift in the expression ratio of the two SRC-1 
splice variants in favour of SRC-1a, without adverse effects and without activation of 
compensatory mechanisms, such as SRC-2 overexpression, or changes in total SRC-1 
expression. Here, we hypothesized that this shift will lead to impaired regulation of CRH 
expression by glucocorticoids in the CeA, and attenuated fear behavior. Our data showed that 
the crh gene became GR resistant after changing the SRC-1 splice variant expression ratio, 
while we observed decreased freezing during fear conditioning testing and increased 
locomotor activity in the open field test. 
Materials and Methods 
 
Animals and stereotactic surgery: 11-week old (at the time of arrival) C57Bl6/j mice were 
purchased from Janvier (Saint-Berthin, France) and used for all experiments. All animal 
experiments were carried out in accordance with European Communities Council Directive 
86/609/EEC and the Dutch law on animal experiments and were approved by the Leiden 
University animal ethical committee (protocol number: 11157). They were housed singly in 
individually ventilated cages upon their arrival and until the second postoperative day, 
thereafter moved to normal cages. Housing conditions were controlled with a 12 h light:dark 
cycle, with lights on at 7 am. Food and water were available ad libitum, except during 
experiments.  Animals were allowed one week to acclimatize in the animal facilities and 
subsequently operated. The operation protocol has been extensively described elsewhere (28). 
Briefly, animals were anesthetized with a cocktail of Hypnorm: Dormicum: demineralized 
H2O in a volume ratio of 1.3:1:3 and a dose of 5 mg/kg. Custom-made boroscillicate needles 
were used for the infusion connected to a Hamilton syringe. One μl of AON targeting exon 22 
of SRC-1e or mismatch AON was infused bilaterally at -1.25 mm anterior-posterior, ±2.95 
mm medio-lateral and -4.75 mm dorso-ventral relative to bregma, at a rate of 0.15 μl/min 
using an injection pump (Harvard apparatus, Holliston, MA, USA). At the end of infusions the 
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injection needle was left inside its injection position for 7 minutes and then retracted slowly. 
Afterwards, the skin incision was sutured and the animals returned to their home cage for 
recovery. All behavioral testing and blood sample collection took place between 9:00-13:00 h. 
At the end of the experiment animals were euthanized with an intraperitoneal injection of 
overdose euthasol (ASTfarma, Oudewater, the Netherlands), followed by decapitation and 
their brains were harvested, frozen in isopentane on dry ice and stored at -80oC.  
Blood samples collection: Two days after the operation and between 9-10:00 AM a blood 
sample was collected from each animal via a small tail incision. Tail blood samples were also 
collected 60 minutes after the start of the open field test, 30 and 120 minutes after the start of 
fear conditioning training and 60 minutes after the start of fear conditioning testing (trunk 
blood). Tail cut and trunk blood samples were collected in pre-cooled EDTA coated 
microvette CB300 tubes (Sarstedt, Etten-leur, the Netherlands) and centrifuged at 13000 rpm 
at 4oC for 15 min in a table top centrifuge. Plasma was collected and stored at -20oC. 
Open field test: Three days after the operation (Figure 1a) animals were placed in a 45 cm x 
45 cm with 45-cm high walls transparent glass box without a lid and were allowed to explore 
freely for 5 minutes. Each trial was recorded by a camera and tracked by the behavioral 
analysis software Ethovision XT 9 (Noldus, Wageningen, the Netherlands). Total distance 
walked, distance walked in a 15 x 15 cm square in the center of the platform and time spent in 
the center of the platform were calculated. 
Fear conditioning test: Fear conditioning apparatus and protocol have been previously 
described elsewhere (29, 30). Briefly, the setup consisted of a 25 cm x 25 cm x 35 cm black 
opaque plexiglas box whose floor consisted of metal grid connected to a shock generator. A 
speaker connected to a noise generator was incorporated in the box. A lamp and a camera 
connected to a computer were placed 20 cm above the box. Each trial was digitally recorded 
with Observer XT (Noldus, Wageningen, the Netherlands). Five days after the operation the 
animals were placed in the box. Every animal was allowed to explore the box for three 
minutes at baseline conditions. Subsequently it received seven cue sessions (Figure 1b). The 
cues consisted of a bright light and a tone for 20 seconds, the last two of which were paired 
with a mild electric shock of 0.4 mA. Between the end of one cue session and the beginning of 
the next there were one minute intervals. Two minutes after the last pairing mice were returned 
to their home cages.  To test their fear responses we returned the animals 48 hours after 
training to the shock box and followed the same protocol as in training, however, this time the 
animals did not receive any electric shocks. We calculated freezing behavior, defined as the 
lack of any movement apart from respiration. 
Subchronic dexamethasone treatment: Starting three days after stereotactic infusion with 
either AONs targeting SRC-1e or mismatch AONs, mice were injected twice per day with 
either dexamethasone 5 mg/kg (Sigma Aldrich, Zwijndrecht, the Netherlands) or with saline 
for five days. At the end of the experiment, the brains were harvested, frozen in isopentane on 
dry ice and stored at -80 oC. The thymi and the adrenals were also stored in PBS at 4oC and 
subsequently weighed. 




polyethylene naphtalate membrane sections (Carl Zeiss, Munich, Germany). Five sections 
were mounted on each slide and stored at -80oC until laser microdissection. Laser 
microdissection was carried out on a Leica laser microdissection microscope as has been 
described elsewhere (31). With the assistance of appropriate software, tissue was selected, 
microdissected and collected in adhesive caps (Carl Zeiss).  
RNA isolation, cDNA synthesis and qPCR: RNA isolation was performed as described 
elsewhere (32). Briefly, RNA was isolated with chloroform and precipitated with isopropanol 
and linear acrylamide. Subsequently, RNA pellets were cleaned with 75% ethanol, dried and 
resuspended with 10 μl of DEPC treated demineralized water. Quality and concentration of 
RNA samples were measured on an experion system (Bio-Rad, Hercules, CA, USA) using 
HighSens analysis kit (Bio-Rad) according to the manufacturer’s instructions. For cDNA 
synthesis 8 μl of RNA in demineralized water treated with diethylpyrocarbonate (Sigma-
Aldrich, Zwijndrecht, the Netherlands) was used in concentrations that ranged from 52 to 961 
ng/μl. RNA samples were first incubated with DNaseI (Promega, Madison, WI, USA) at 37oC 
for 30 min in order to remove possible DNA contamination. After incubation 1 μl of DNaseI 
stop solution (Promega) was added to each sample followed by incubation at 65  oC for 10 min 
to deactivate the enzyme. RNA samples were reverse transcribed with iScript cDNA synthesis 
kit (Bio-Rad). Briefly, 4 μl of 5 times iScript reaction mix, 1 μl of iScript reverse transcriptase 
and 5 μl of Nuclease-free H2O were added to 10 μl of DNase I treated RNA. Sub-sequently 
samples were incubated for 5 min at 25°C followed by 30 min at 42°C and finally 5 min at 85°
C in a My Thermal Cycler (Bio-Rad) machine. Quantitative polymerase chain reaction 
(qPCR) was performed for assessment of gene expression in the CeA of AON injected mice. 
A 1:1 dilution of cDNA in autoclaved demineralized water was used for qPCR. The 
quantification of cDNA was performed on a LightCycler 2.0 (Roche Applied Science, Basel, 
Switzerland) using LC FastStartDNA MasterPLUS SYBR Green I (Roche). 2.5 μl of cDNA 
was added to a mix of 2 μl 5 times Sybr green mix, 1 μl of both forward and reverse primers 
(5 μM) and 3.5 μl nuclease-free water, in LightCycler Capillaries (20 μl, Roche). All 
measurements were performed in duplicate. The PCR program comprised 10 min at 95°C 
followed by 45 cycles of denaturation at 95°C for 10 sec, annealing at 60°C for 10 sec and 
elongation at 72°C for 10 sec, with a subsequent dissociation stage (from 65°C to 95°C, at a 
rate of 0.1°C/sec). The SRC-1 splice variants were quantified as an expression ratio of SRC-
1a/SRC-1e; the expression of total SRC-1 was normalized against β-actin. Quantification of 
relative expression was calculated using the Pfaffl method (33) and normalized against the 
control group (mismatch AON). The forward and reverse primer sequences were: SRC-1a 5’-
CCTCTACTGCAACCAGCTCTCGTC-3’ and 5’-TGCTGCACCTGCTGGTTTCCAT-3’, 
SRC-1e: 5’-TGCAACCAGCTCTCGTCCACTG-3’ and 5’- 
GCTCCTCTAGTCTGTAGTCACCACA-3’, b-actin: 5’-CAACGAGCGGTTCCGATG-3’ 
and 5’-GCCACAGGATTCCATACCCA-3’. 
Radioimmunoassay (RIA): Plasma corticosterone levels were determined with 
Radioimmunoassays using 125I RIA kits (MP Biochemicals, Santa Ana, CA, USA) as per the 
manufacturer’s instructions.  
In situ Hybridization: Non-isotopic double label semi-quantitative in situ hybidrization was 
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performed using the Panomics View-RNA method (Affymetrix, Santa Clara, CA, USA). 
Probe sets against GR (type 6 probe) and CRH (type 1 probe) mRNA were designed by the 
manufacturer. 12 µm thick section cryosections were mounted on Superforst plus microscope 
slides (Menzel Gläser, Braunschweig, Germany). Upon thawing the sections were postfixed in 
4% formaldehyde (Sigma-Aldrich, Zwijndrecht, the Netherlands). Pre-incubation steps were 
Figure 1. A. Schematic representation of the experimental design. The animals were operated 7-9 days 
after arrival in the animal facilities (day 0). Two days later basal blood samples were drawn. On day 3 
they were introduced to an open field test. On day 5 and day 7, fear conditioning training and testing, 
respectively, took place. B. Fear conditioning protocol: The mice were allowed 3 minutes to explore the 
(Figure 2 continued) shock box. Afterwards, they were exposed to a strong light and sound for 20 
seconds the last 2 of which coincided with a mild footshock. The interval between the end of one cue 
session and the beginning of the next was one minute. On training, the mice were exposed to 6 cue/
shocks in total. On testing, the same protocol, but without shocks, was used. C. qPCR validation of exon 
skipping 7 days after an AON injection. The SRC-1a:SRC-1e ratio is significantly different between the 





performed according to the manufacturer’s instructions (https://www.panomics.com/products/
rna-in-situ-analysis/viewrna-ish-tissue-assay/how-it-works). Hybridization of the probes took 
place for 4 hours in a Startspin thermobrite stove (Iris sample processing, Westwood, MA, 
USA). After hybridization slides were kept in storage buffer overnight. The next day linear 
amplification and visualization steps were performed following manufacturer’s instructions. 
Slides were lightly counterstained with Mayer’s hematoxylin, and DAPI (1 minute incubation 
at 3 µg/ml), and embedded in Innovex mounting medium (Innovex Biosciences, USA).  
Slides were visualized using a Leica DRMA fluorescence microscope (Leica, Germany).  For 
visualization of the red fluorophore, the Texas Red filter (excitation 542-582 nm, emission 
604-644 nm) was used. For the blue fluorophore, the Cy5 filter (excitation 604-644 nm, 
emission 672-712 nm) was used. Ideally, the red fluorophore should be viewed under 
excitation 530 ± 20 nm, emission 590 ± 20 nm, and blue fluorophore with excitation 630 ± 20 
nm and emission 775 ± 25 nm. Images were acquired through the software program 
ColourProc. For the images used for analysis, pictures were taken without stretching contrast. 
From each animal, a slice was selected and pictures were taken from the left and right CeA 
and the left and right PVN. 
Statistical analysis: When two groups were compared, student’s t-tests were performed. 
Differences with P values below 0.05 were considered statistically significant. For the effect of 
AONs and glucocorticoids on CRH expression a two-way ANOVA was performed with 




Isoform expression ratio:  In order to validate successful shifting of the SRC-1 splice variant 
ratio in the present experiment, we analyzed tissue from mice injected with AONs seven days 
earlier (n = 4-5 per group). qPCR analysis revealed that the SRC-1a:SRC-1e expression ratio 
was significantly shifted in favour of SRC-1a (Figure 1c). 
Behavior: To assess basal anxiety-like behavior, we exposed animals to an open field test. 
Animals injected with AONs targeting SRC-1e had longer total walking distances (Figure 2a), 
however, no difference was found in percentage of time spent or distance walked in the center 
of the open field (Figure 2b). 
We used a fear conditioning paradigm to assess the acquisition and consolidation of emotional 
memory after a shift in the SRC-1a:SRC-1e. In training, a significant trial effect and a group 
effect were found (Figure 2c) with animals injected with AONs targeting SRC-1e show 
increased freezing responses compared to control animals. However, animals injected with 
AONs targeting SRC-1e displayed reduced freezing upon re-exposure to the same chamber on 
testing day (Figure 2d). No difference was found in freezing behavior after presentation of the 
cue (Supplementary Figure 1). Moreover, we correlated the expression ratio of the two 
isoforms with the total distance walked in the open field experiment, in the subset of mice 
from which we had the SRC-1a:SRC-1e expression data. A strong positive correlation was 
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Figure 2. Behavioral profile of animals injected with SRC-1e skip AONs in the CeA. A. Total distance 
walked in the open field was not significantly different between the two groups (two-tailed t-test, t(27) = 
2.3, p < 0.05, n = 13-16 per group). B. There was no difference in percent of distance walked in the 
center of the open field, between the groups (two-tailed t-test, t(27) = 0.644, p > 0.5, n = 13-16 per group). 
C. There was a  significant (albeit small) treatment effect and a trial effect in CUE freezing during 
training (treatment: F(1,120) = 11.10, p = 0.001, trial: F(5,120) = 18.51, p = 0.0001, n = 9-13, per group). D. 
SRC-1e AONs reduced contextual fear memory consolidation measured as freezing response during 
reexposure to the footshock chamber (two-tailed t-test, t(18) = 2.313, p < 0.05, n = 10 per group). E. A 
significant correlation was found between SRC-1a:SRC-1e mRNA expression ratio and total distance 
walked in the open field (r2 = 0.78, p<0.05, n = 6). 
found; animals that had higher SRC-1a:SRC-1e expression ratios walked longer total dis-




Figure 3. Lack of differential HPA axis regulation under basal conditions or in response to acute stress 
by SRC-1 isoform switching. A. Basal corticosterone levels do not differ between treatments (two-tailed 
t-test: t(15) = 1.121, p = 0.29, n=8-9 per group). B. Corticosterone plasma level curves in response to acute 
stress. We only found a time point effect (F(1,20) = 39.85, p<0.001), but no group (F(1,20) = 0.356, p = 0.56) 
or interaction effects (F(1,20) = 0.27, p = 0.60). 
 
 
Figure 4. A. CRH mRNA in situ hybridization. In animals injected with scrambled AONs chronic 
dexamethasone treatment resulted in upregulation of CRH expression, which was blocked by SRC-1e 
skip AONs. Two-way ANOVA: AON effect, F(1,17) = 54.46, p<0.0001, Glucocorticoid treatment effect, 
F(1,17) = 75.51, p<0.0001, interaction effect, F(1,17) = 56.14, p<0.0001, n = 5-7 per group.  Bonferroni post 
hoc test: ***, p<0.001. B. CRH mRNA expression in the PVN. Treatment with dexamethasone 
significantly reduced CRH mRNA expression in the PVN (F(1,12) = 27.37, p<0.001), while  no AON 
effect was present (F(1,12) = 3.47, p>0.08). C. Representative image of CRH mRNA in-situ hybridization 




CRH expression after glucocorticoid treatment: In order to test the hypothesis that the 
upregulation of CRH after glucocorticoid treatment is attenuated by SRC-1A, we compared 
the effects of 5 days of dexamethasone treatment compared to saline after injection with 
AONs targeting SRC-1e or scrambled AONs. Our results showed that in the scrambled AONs 
group there was a three-fold upregulation of CRH mRNA expression after treatment with dex-
amethasone, which was absent in the animals treated with AONs targeting SRC-1e (Figure 
4a). In the PVN, the expected downregulation of CRH expression in response to glucocorti-
coids was found, independent of AON treatment (Figure 4b). Glucocorticoid treatment 
strongly reduced thymus weight in both groups, likewise indicating no differences in dexa-
methasone dosing between the groups (Figure 5a-b).  
Plasma corticosterone levels: Basal corticosterone levels were not different between the 
groups (Figure 3a). Similarly, no differences between the two AON treatments were found 
after 30 or 120 minutes after fear conditioning training (Figure 3b). 
Figure 5. Effects of glucocortiocid treatment on thymus weight: A) There was a dexamethasone treat-
ment effect on the weight of the thymi of the animals, independent of AON treatment (Glucocorticoid 
effect: F(1,32) = 41.01, p < 0.0001, AON treatment: F(1,32) = 1.612, p = 0.213, n = 8-10 per group). B) 
After correction for body weight, similar effects were observed (Glucocorticoid effect F(1,34) = 28.10, p < 






In this study we manipulated the splicing of SRC-1 and we investigated its effect on stress 
responses and regulation of crh expression in the CeA by glucocorticoids. Here, we targeted 
exon 21 of the Ncoa1 gene which leads to a shift towards higher expression of SRC-1a 
mRNA. We confirmed our previous finding (28) that seven days after a single injection of 
AONs targeting SRC-1e the expression ratio of two isoforms is shifted in favour of SRC-1a. 
Moreover, we found an effect of the expression ratio shift on contextual fear conditioning 
consolidation and a trend towards reduced basal anxiety as shown in an open field test. We 
also showed that the crh gene in the CeA became strongly resistant to the synthetic 
glucocorticoid dexamethasone. The data show that aspects of glucocorticoid effects on brain 
function may depend on downstream effector components in the molecular signal transduction 
pathway of the GR. They moreover suggest that these pathways may be targeted to overcome 
potentially pathogenic effects of excess glucocorticoids in stress-related disease. 
Our hypothesis on the effects of changing the ratio in SRC-1 splice variants was based on a 
number of arguments. SRC-1a contains an additional nuclear receptor interaction domain that 
is possibly associated with a different affinity for the ligand-activated GR (36). In addition, the 
SRC-1A specific domain may lead to binding of different transcriptionally active proteins 
compared to the 1E isoform (34). Accordingly, SRC-1a can potentiate repression of the crh 
promoter after glucocorticoid treatment in AtT-20 cells, whereas SRC-1e lacks this repressive 
activity (25). Moreover, in SRC-1 KO animals, regulation of CRH expression in the CeA and 
the PVN by glucocorticoids is disrupted (23).  Here, we observed a very strong abrogation of 
dexamethasone-induced CRH mRNA expression upregulation in the CeA which is in line with 
previous studies describing the effects of SRC-1a on the CRH promoter and similar to what 
has been observed in SRC-1 KO animals (23, 25). In contrast to SRC-1 KO animals, we did 
not observe a considerable effect of SRC-1e exon skipping after treatment with saline. This 
may have been due to the remaining expression of SRC-1e which may be adequate or even 
necessary for CRH expression under these conditions. The similar effects of dexamethasone 
on crh repression in the PVN, and the effects on thymus weight seem to exclude differences in 
steroid exposure as a cause of the observed differences.  
 
One issue that needs to be taken into account is the stronger binding of the SRC-1a NR-IV box 
to the agonist bound GR compared to the central NR boxes, that has been shown in in vitro 
systems (35, 36). This may mean that the observed effect on crh expression and behavior may 
be beyond simple stoichiometry of SRC-1a and SRC-1e. Therefore, the effect of isoform 
switching may be higher than what would have been expected simply by the relative 
expression of the two isoforms. Thus, we observed a shift towards SRC-1a dependent effects 
of GR, such as repression of the crh promoter (25). 
There were a number of behavioral effects of our manipulation. In the open field, the shift 
towards SRC-1A induced increased locomotor behavior that was proportional to the ratio 
between the splice variants. Moreover, after the 1e exon skip, the mice showed reduced 
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contextual freezing, even if both contextual and cue fear conditioning depend on amygdala 
function. A possible explanation for that could be the higher sensitivity of contextual fear 
conditioning to disruptions, and/or a ceiling effect for the cue conditioning (37). During 
training, SRC-1e AON injected animals showed higher reactivity to cue, while in testing the 
two groups had similar levels of freezing, something that may point to decreased consolidation 
of cue fear conditioning as well. Nevertheless, the strong effect on contextual fear 
conditioning suggests an important role of SRC-1 isoforms in fear memory consolidation, 
probably in relation to the genomic effects of glucocorticoids.  
While previous studies in SRC-1 KO animals have found strong effects on their endocrine 
phenotype, they were accompanied by relatively mild behavioral differences (38, 39). This 
discrepancy has been attributed to possible developmental compensatory mechanisms such as 
SRC-2 upregulation in the absence of SRC-1 (23, 40). Here, we did not expect the 
development of strong compensatory mechanisms since we used a local manipulation on adult 
animals and a short term experimental setup that lasted up to seven days after AON treatment. 
As we have previously shown this manipulation does not change total SRC-1 expression and 
is not accompanied by upregulation of SRC-2 (28). 
The mechanism that brings about the differences in crh expression and behavior may involve 
differential histone modification. The additional protein domain of SRC-1a contains a histone 
methyltransferase recruitment domain. Thus, upregulation of SRC-1a expression could well 
lead to higher histone methylation. Differential HAT activity may also result in decreased 
histone acetylation and differences in the expression of genes important for proper memory 
consolidation, or a direct effect of decreased crh expression after fear conditioning training. 
We did not find a group effect on corticosterone levels at any time point which is in 
accordance with previous studies showing differential regulation of the HPA axis by the 
amygdala mainly in settings of chronic stress and sporadically after acute manipulations (5, 
12, 13, 41). The lack of corticosterone plasma levels under basal conditions or after stress 
indicates that the local manipulation in the CeA did not block proper HPA axis function. On 
the other hand, the observed changes in fear memory under comparable levels of 
corticosterone suggest that the different relative expression ratio in the CeA may have changed 
its sensitivity to glucocorticoids. This is further highlighted by the abrogation of crh 
expression upregulation by dexamethasone in SRC-1e AON injected animals. 
Based on our findings we suggest that a shift in the expression ratio of SRC-1a:SRC-1e may 
change the effects of GR on downstream targets in the context of stress and high 
glucocorticoid levels in the CeA by modifying its sensitivity to glucocorticoids and its 
selectivity regarding possible transcriptional pathways. This may have therapeutic 
implications in disorders characterized by high glucocorticoid levels such as psychotic 
depression (42), in relation to the recruitment and interaction of GR and its coregulators, either 
by changing the availability of the relevant coregulators [present study and (23)], or by 
pharmacologically targeting GR with appropriate ligands that can modulate its interactions 
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Supplementary figure 1. Percentage of time freezing in testing during the intervals between the cues (A) 
and during the presentation of the cues (B). A.  Freezing % decreased over testing trials during 
reexposure to the shock box. No effect of AON treatment was found, but only a significant effect of trial 


















I. Zalachorasa, R. Houtmanb, E. Atuchac, R. Devosd, A.M.I. Tijssene, P. Huf, P. Lockeyd, N.A. 
Datsong, J. Belanoffh, P.J. Lucassenf, M. Joëlsi, E.R. de Kloete, B. Roozendaalc H. Hunth, O.C. 
Meijera  
 
aDept of Endocrinology and Metabolism and Einthoven Laboratory for Experimental Vascular Medicine, Leiden 
University Medical Center, PO Box 9600, 2300 RA Leiden, The Netherlands  
b Pamgene International, PO Box 1345, 511HH Den Bosch, The Netherlands 
cDepartment of Cognitive Neuroscience, Radboud University Nijmegen Medical Centre, and Donders Institute for 
Brain, Cognition and Behaviour, Radboud University Nijmegen, Geert Grooteplein-Noord 21, 6525 EZ Nijmegen, 
The Netherlands 
dArgenta Discovery, 8/9 Spire Green Center, Harlow, Essex, CM19 5TR UK 
eDivision Medical Pharmacology, Leiden/Amsterdam Center for Drug Research, PO Box 9502, 2300 RA, Leiden, 
The Netherlands  
fSwammerdam Institute for Life Sciences, Science Park 904, 1098 XH Amsterdam, The Netherlands 
g Dept of Human Genetics, Leiden University Medical Center, PO Box 9600, 2300 RA Leiden, The Netherlands 
hCorcept Therapeutics, Menlo Park CA, USA 
iRudolf Magnus Institute for Neuroscience, University Medical Center Utrecht, Universiteitsweg 100, 3584 GC 
Utrecht, The Netherlands 
 
Published in Proceedings of the National Academy of Science, 2013, 110(19):7910-5. doi: 
10.1073/pnas.1219411110 
Differential targeting of brain 
stress circuits with a selective 





Glucocorticoid receptor (GR) antagonism may be of considerable therapeutic value in stress-
related psychopathology such as depression. However, blockade of all GR-dependent 
processes in the brain will lead to unnecessary and even counteractive effects, such as elevated 
endogenous cortisol levels. Selective GR modulators are ligands that can act both as agonist 
and as antagonist, and may be used to separate beneficial from harmful treatment effects. We 
have discovered that the high-affinity GR ligand C108297 is a selective modulator in the rat 
brain. We first demonstrate that C108297 induces a unique interaction profile between GR and 
its downstream effector molecules, the nuclear receptor coregulators, as compared to the full 
agonist dexamethasone and the antagonist RU486 (mifepristone). C108297 displays partial 
agonistic activity for the suppression of hypothalamic corticotropin-releasing hormone (CRH) 
gene expression, and potently enhances GR-dependent memory consolidation of training on an 
inhibitory avoidance task. In contrast, it lacks agonistic effects on the expression of CRH in 
the central amygdala and antagonizes GR-mediated reduction in hippocampal neurogenesis 
after chronic corticosterone exposure. Importantly, the compound does not lead to 
disinhibition of the hypothalamus-pituitary-adrenal axis. Thus, C108297 represents a novel 
class of ligands that has the potential to more selectively abrogate pathogenic GR-dependent 





Adrenal glucocorticoid hormones are essential for adaptation to stressors, but prolonged or 
excessive exposure to glucocorticoids has been consistently implicated in the development of 
stress-related psychopathologies, such as depression (1). Antagonism of their most abundant 
receptor type, the glucocorticoid receptor (GR), can be beneficial in stress-related psychiatric 
disease, e.g. in order to abrogate psychotic and depressive features in patients with Cushing’s 
syndrome (2) and in patients suffering from psychotic major depression (3). The GR is widely 
distributed in the brain (4) where it affects many different processes including learning and 
memory (5, 6) adult neurogenesis (7), and neuroendocrine negative feedback regulation (8). 
Although GR antagonism of particular processes may be of therapeutic benefit, blocking other 
GR-mediated effects may actually counteract the potential therapeutic efficacy. For example, 
GR antagonists interfere with glucocorticoid negative feedback and lead to increased cortisol 
levels (9, 10), which inadvertently activate mineralocorticoid receptors to which 
corticosteroids bind in the brain, and diminish the efficacy of antagonism at relevant sites. 
The GR is a nuclear receptor (NR) that affects gene transcription through a number of 
transcriptional mechanisms. For several NRs ‘selective receptor modulators’ exist. These can 
act as an agonist as well as an antagonist depending on the tissue or gene targets, with the 
estrogen receptor ligand tamoxifen as a well-known example (11). Selective GR modulators 
(SGRMs) may be used to separate beneficial from unwanted glucocorticoid effects. Anti-
inflammatory SGRMs with diminished side effects have been pursued, based on the 
distinction between GR effects that depend on direct DNA binding and those that take place 
via protein-protein interactions between the GR and other transcription factors (12). Selective 
receptor modulation may also be based on specificity of ligand-induced interactions between 
the GR and its major downstream effector molecules, the NR coregulators (13).  
Many receptor-coregulator interactions depend on the receptor’s ligand-binding domain (GR-
LBD) and on specific coregulator amino acid motifs that contain an LXXLL sequence, known 
as ‘Nuclear Receptor-boxes’ (NR-boxes). These interactions are governed by the conformation 
that is induced by a particular ligand and may be screened for in vitro (14). The importance of 
individual coregulators for brain GR function is largely unknown, but an exception is steroid 
coactivator-1 (SRC-1 or NCoA1). SRC-1 is necessary for GR-mediated negative gene 
regulation in the hypothalamus-pituitary-adrenal (HPA) axis (15, 16),  and for the induction of 
corticotropin releasing hormone (CRH) gene expression in the central nucleus of the amygdala 
(CeA)(16). Its two splice variants SRC-1A and 1E seem to exert opposite effects on CRH 
expression (17). Selective activation of GR interactions with SRC-1A, brought about via an 
SRC-1A specific NR-box, would be expected to separate GR-mediated effects on CRH 
expression in the hypothalamus and amygdala. 
Here we show proof-of-principle for selective GR modulation in the brain with relevance for 
stress regulation, cognition and psychopathology. We show that a previously described 




distinguishes between the two splice variants of SRC-1. C108297 (or compound 47 from ref 
(18)) has a Ki of 0.9 nM for GR, and of >10 µM for progesterone, mineralocorticoid and 
androgen receptors (18). It shows GR antagonism in relation to GR-dependent CRH mRNA 
regulation in the amygdala and corticosterone-induced reduction in hippocampal neurogenesis.  
The agonistic effects of C108297 include enhanced memory consolidation of emotionally 
arousing training and a suppression of hypothalamic CRH expression. The compound does not 
lead to net inhibition of glucocorticoid negative feedback as indicated by unaltered circulating 
corticosterone levels.  
 
Materials and Methods 
 
Peptide interaction profiling: Interactions between the GR-LBD and coregulator NR-boxes 
were determined using a MARCoNI assay with 55 immobilized peptides each representing a 
coregulator-derived NR-box (PamChip #88011, Pamgene Int, Den Bosch, The Netherlands) 
(14). Each array was incubated with a reaction mix of 1nM GST-tagged GR-LBD, 
ALEXA488-conjugated GST-antibody and buffer F (PV4689, A-11131 and PV4547; 
Invitrogen), and 1 µM DEX, RU486, C108297, or solvent (DMSO, 2%). Incubation was 
performed at 20°C in a PamStation96 (PamGene). GR binding to each peptide on the array, 
reflected by fluorescent signal, was quantified by tiff image analysis using BioNavigator 
software (PamGene). 
Two-hybrid studies: To generate fusions to the DNA binding protein Gal4, partial 
coregulator cDNAs were cloned into the pCMV-BD vector (Stratagene): SRC-1 residues 621-
1020, SRC-1A residues 1021-1441, and NCOR1 residues 1962-2440 (45) . COS-1 cells were 
transfected using Lipofectamine2000 (Invitrogen) with a combination of a Gal4-coregulator 
fusion plasmid, the pGR-VP16 transactivator plasmid and the pFR-Luc reporter gene 
(Stratagene). Twenty four h after transfection the medium was replaced with medium 
containing 0.1% DMSO, DEX, RU486, or C108297 (all 1 µM). The next day the medium was 
replaced with 0.1ml Hank’s Balanced Salt Solution plus 0.1ml Steady light (Perkin Elmer) and 
luminescence was counted on a Topcount instrument (Packard). 
Animal experiments: Animal experiments were carried out in accordance with the EC 
Council Directive of November 24 1986 (86/609/EEC), certificates and licenses granted under 
the Animals (Scientific Procedures) Act 1986 by the UK Home Office, or approved by the 
Local Committees for Animal Health, Ethics, and Research of the Dutch universities involved. 
Male rats were used, housed in temperature-controlled facilities on a 12 h day-night schedule 
with food and water available ad libitum. Modes of administration and duration of drug 
treatment differed in accordance with the standards used in the different in vivo paradigms. 
Binding to brain GR: Group-housed Sprague Dawley rats were orally dosed with 
corticosterone (3 mg/kg) or C108297 (20 mg/kg and 100 mg/kg) dissolved in 10% 
DMSO/90% methylcellulose (0.5% w/v). After 3 h the rats were sacrificed and half-brains 
were snap-frozen in liquid nitrogen. For receptor binding, half-brains were homogenized in 
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freshly prepared buffer [0.2 M KH2PO4 (pH 7.4), 1 mM EDTA, 1 mM DTT; 4 °C], 
containing a protease inhibitor mixture (Sigma; P8340; 50 μL/g tissue) and phosphatase 
inhibitor mixtures 2 and 3 (Sigma; P5726and P0044; 1:100 dilution), using a Bead Ruptor at 4 
°C for 15 min. Free GR ligands were cleared by incubation of 500 μL of homogenates (15-min 
incubation on ice) with dextran-coated charcoal (Sigma; C-6197) and centrifuged in a bench 
top Microfuge (17,000 × g; 4 °C; 10min). Receptor binding was determined by incubating 50 
μL of homogenate with 2.5nM [3H]dexamethasone (Amersham; TRK645) at 4 °C for 18 h in 
a total volume of 100 μL of assay buffer [10 mM potassium phosphate buffer (pH 7.6), 
containing 5 mM DTT, 10 mM sodium molybdate, 100 μM EDTA, and 0.1% BSA). 
Nonspecific binding was determined by addition of 20 μM unlabeled dexamethasone. 
Unbound ligand was removed by addition of 15 μL of 10% dextran-coated charcoal and 
centrifugation at 3,080 × g for 10 min at 4 °C. The supernatant (65 μL) was transferred to a 
Packard Optiplate, and 125 μL of MicroScint40 was added. [3H]Dexamethasone activity was 
quantified as counts per minute by counting on a Perkin Elmer Topcount. 
Hippocampal gene expression: The other halves of the brains were cut at 200-μm-thick 
coronal sections. Sections were mounted on glass slides (Gerhard Menzel). Eight tissue 
punches were taken from the CA1-CA2 area of the hippocampus with a Harris UniCore 
hollow needle (Electron Microscopy Sciences; 1.2 mm internal diameter), with one punch per 
section starting around 2.56 mm posterior to Bregma (46). Tissue was stored in TRIzol 
(Invitrogen) at –80 °C until further processing.RNA isolation, cDNA synthesis and qPCR have 
been described elsewhere (47). Validated hippocampal GR target genes were selected from 
micro-array analysis (Rat Genome 230 2.0 Arrays; Affymetrix, Santa Clara, USA) (22). 
Quantitative PCR was performed on a LightCycler 2.0 (Roche Applied Science) using LC 
FastStartDNA MasterPLUS SYBR Green I according to the manufacturer’s instructions 
(Roche). Tubulin β2a (Tubb2a) was used to normalize expression (6). The forward and reverse 
primers used were, respectively, as follows: 5′-GCAAATCCGGCGCATCTCAG-3′ and 5′-
TGCGGTGGTCTGGCAATTCT-3′ for Drd1a (coding for the dopamine 1A receptor), 5′-
GGTCACAGCGGCAGATAAAAAGAC-3′ and 5′-TCGGCATTGCGAGTTCCAG-3′ for 
Bdnf and 5′-GAGGAGGGCGAGGATGAGGCTT-3′ and 5′-
GACAGAGGCAAACTGAGCACCAT-3′ for Tubb2a. Tubulin β2a (Tubb2a) was used to 
normalize expression (48).  
Subchronic treatment: agonism in relation to CRH and the HPA axis: Group-housed 
Wistar rats (200-220 gram, Harlan, The Netherlands) underwent adrenalectomy in the 
morning as described (49). One week later, animals were treated twice daily (s.c., 1 ml/kg) 
with vehicle (polyethylene glycol-300), C108297 (20 mg/kg) or DEX (0.5 mg/kg) (25). On 
day 5, three h after the morning injection, half of the animals underwent 30 min of restraint 
stress. A tail cut sample was collected 15 min after the onset of restraint. Animals were killed 
by decapitation either under basal conditions, or at 30 min after onset of the restraint. CRH 
and c-fos mRNA, and CRH hnRNA were quantified by in situ hybridization on whole PVN 
and CeA as described previously (25). Corticosterone and adrenocorticotropin (ACTH) were 
measured by radioimmuno assay (MP Biomedicals Inc., CA., USA). 




were as described above but in intact rats, this time using RU486 (40 mg/kg) as a reference 
drug. Tail cuts that were performed at 08:00 h and 20:00 h of day 4 for basal plasma 
corticosterone levels. To determine acute stress responses in naïve rats, we subjected rats to an 
acute 0.4 mA footshock in an inhibitory avoidance shock box (49), with or without a single 
pretreatment with the doses of RU486 and C108297 that were used in the subchronic setting. 
Neurogenesis: Group-housed Wistar rats (200 grams) were habituated to the animal facility 
for 10 days. Corticosterone (Sigma, C-2505; 40 mg/kg) or vehicle (arachidus oil) was injected 
(s.c.) daily at 09:00 h for 21 days. Animals received C108297 (50 mg/kg) or vehicle (0.1% 
ethanol in coffee cream (Campina, Woerden, The Netherlands)) by gavage on the final 4 days 
of corticosterone treatment at 09:00 h and 16:00 h. Animals were sacrificed one day after the 
last treatment. All animals received 5-bromo-2-deoxyuridine (BrdU) (200 mg/kg, i.p) on day 
1, 3 h after the first corticosterone injection. Tissue processing for immunostainings was 
performed as described (50). Data on vehicle treated groups were also reported elsewhere (50). 
Inhibitory avoidance behavior: One-trial inhibitory avoidance training and retention was 
performed as described (30), using single-housed Wistar rats (300-350 g, Charles River, 
Germany)  and a footshock intensity of 0.5 mA for 1 s. RU486 (40 mg/kg) or vehicle 
(polyethylene glycol) was administered (s.c.) one h before the training session. C108297 (20 
mg/kg) or corticosterone (1 mg/kg) was dissolved in DMSO and administered (100 µl, s.c.) 
immediately after the training trial, so that treatment did not interfere with memory 
acquisition. Retention was tested 48 h later. A longer latency to enter the former shock 
compartment with all four paws (maximum latency of 600 s) was interpreted as better 
memory.  
Statistical analysis: Data were analysed using Graphpad Prism using (as appropriate) 1- or 2-
way ANOVA followed by Tukey’s/Bonferoni post hoc test respectively, and Kruskal-Wallis 
for data that deviated from a normal distribution. 
Results  
 
C108297 displays selective modulator activity in vitro: To explore possible selective 
modulator activity of C108297 based on the GR-coregulator interactions, we used a 
MARCoNI peptide array (14) to determine interactions between (recombinant) GR-LBD and 
coregulator NR boxes (figure 1A). Reference drugs were the full agonist dexamethasone 
(DEX) and the prototypical antagonist RU486 at saturating doses. Without ligand, GR 
displayed only weak interactions with coregulator motifs. DEX induced significant 
interactions between GR-LBD and 28 motifs from coactivator proteins. RU486 induced 
modest interactions with motifs from two corepressor proteins, NCoR and SMRT (19). 
C108297 induced interactions with a subset of the motifs that were recruited after DEX 
treatment, suggesting selective modulator activity. C108297 did not induce interactions with 
NCoR and SMRT motifs. For quantitative analysis, see figure 2. The partial recruitment of 
coregulator motifs of C108297-bound GR suggests that the compound combines agonistic and 
antagonistic effects (dependent on the gene-specific coregulator use by GR). 
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Figure 1. C108297 behaves like a selective modulator in vitro and in vivo.  A. Ligand-induced 
interactions between the GR-LBD and coregulator motifs. DEX induced many interactions compared 
with DMSO. RU486 induced modest interactions with corepressor motifs (black arrow: NCoR1). 
C108297 showed an intermediate profile. GR-LBD interactions with the central motifs from SRC-1 were 
much weaker or absent (boxed), but others were retained (white arrow indicates SRC-1 motif IV).  B. 
Hippocampal Drd1a mRNA was regulated by corticosterone after vehicle but not C108298 treatment. C. 
BDNF mRNA was down-regulated by both corticosterone and C108297. Asterisks indicate significant 
differences from the control group (*P < 0.05; **P < 0.01). 
C108297 reaches the brain: We tested whether C108297 can reach the brain in order to 
affect GR-dependent processes. Three h after oral treatment of rats, C108297 (20 mg/kg) led 
to 35 ± 15% occupancy of brain GR binding determined ex vivo in 1 hemisphere, compared to 
the negative control. This level of occupancy did not differ from that observed for the positive 
control of 3 mg/kg corticosterone (well above the ED50 of 0.6 mg/kg (20)), which resulted in 
44 ± 15% GR occupancy. This degree of occupancy is considered effective for many 
corticosterone effects via GR (e.g. (21)), and the dose of 20 mg/kg C108297 was used in all 
other in vivo experiments described below, with the exception of the work on neurogenesis 
that was initiated earlier. 
C108297 displays gene-specific agonism and antagonism on GR target genes in vivo: To 
confirm gene-specific antagonism of C108297, we tested mRNA regulation of two previously 
characterized hippocampal GR target genes (22). Rats were treated with 3 mg/kg 
corticosterone with or without pretreatment with C1082987 (20 mg/kg), or with C108297 
alone. For Drd1a mRNA (coding for the dopamine 1A receptor) 2-way ANOVA showed main 




endogenous corticosterone was present). Drd1a mRNA was significantly lower after 
corticosterone (3 mg/kg) treatment, but not after (pre-)treatment with C108297 (20 mg/kg) 
(figure 1B). For BDNF regulation, 2-way ANOVA showed main effects of corticosterone, 
C108297 (both p < 0.05) and an interaction (p < 0.001). C108297 by itself down-regulated 
BDNF mRNA levels, and did not prevent the corticosterone effect (figure 1C).  
C108297 distinguishes between SRC-1 splice variants: Out of many potential coregulators 
of GR, SRC-1 is among the few that have been linked to regulation of specific GR target 
genes (15, 16). Its splice variants SRC-1A and 1E may mediate different effects in relation to 
stress adaptation (17). As C108297 seemed to differentiate between the SRC-1 splice variants, 
we focused on these for further analysis. Quantitative analysis of the MARCoNI data showed 
that C108297 differentiates between the three NR-boxes that are common to the two SRC-1 
splice variants and NR-box IV that is unique to SRC-1A (23) (figure 2A). Two-way ANOVA 
indicated highly significant differences between ligands, motifs and a strong interaction 
between the two (p < 0.001 for main effects and the interaction). DEX was able to induce 
strong GR interactions with all four SRC-1 motifs, but C108297 induced substantial agonist-
like binding only for the SRC-1A specific NR-box (figure 2B), confirming potentially 
selective recruitment of these splice variants by the GR-C108297 complex. 
We validated the ligand-directed differential recruitment of SRC-1 splice variants using larger 
protein fragments in a two-hybrid system in mammalian COS-1 cells (figure 2C). Two-way 
ANOVA showed significant effects of drug, protein fragment and an interaction (p < 0.001 for 
all effects). Both DEX and C108297 induced a strong GR-LBD interaction with a 420 amino 
acid fragment containing the SRC-1A specific NR-box IV. DEX, but not C108297, induced 
interactions with the SRC-1 domain containing the three central NR-boxes. A fragment from 
the corepressor NCoR was recruited by GR-LBD only after incubation with the antagonist 
RU486. Thus, the ligand selective interactions of GR also occurred with large protein 
fragments in cell line context. 
C108297 has selective partial agonist activity in the brain of adrenalectomized rats: The 
selective modulator type interactions of GR with SRC-1 variants led to the hypothesis that 
C108297 in vivo acts as an agonist for GR-mediated regulation of the Crh gene in the core of 
the HPA axis, but not in the CeA (17, 24). To test agonism, we used adrenalectomized rats in a 
5 day treatment paradigm in which half of the animals underwent a single restraint stress on 
day 5, 30 min before sacrifice. This paradigm allows measurement of a number of both basal 
and stress-induced HPA-axis variables (25). It is well established that CRH expression in the 
hypothalamic paraventricular nucleus (PVN) and CeA both respond to treatment with our 
control agonist DEX, but in an opposite direction (26).  
CRH mRNA in both brain regions responded to drug but not to acute stress (2-way ANOVA, 
drug effect PVN: p < 0.001; CeA: p = 0.011, stress effect not significant). In the PVN (figure 
3A) CRH mRNA was strongly suppressed by DEX. C108297 also showed modest agonism 
that reached significance in the stressed animals. CRH mRNA in the CeA (figure 3B) was 
increased after DEX treatment in non-stressed animals, but unaffected by C108297. In the 
stressed rats the differences between the treatment groups failed to reach significance. A more 
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Figure 2. SCR-1 splice variant 1A is selectively recruited by GR-C108297.   A. Protein structure of SRC-
1 harboring three NR central boxes (roman numerals). SRC-1A harbors a repressor function (RF) and the 
additional NR-box IV. Protein fragments marked by dotted lines refer to C.  B. MARCoNI quantification 
showed that unlike DEX, C108297 induced interactions only between GR and NR-box IV.  C. In a two-
hybrid assay only DEX induced interaction with the SRC-1 fragment common to both splice variants. 
The SRC-1A–specific protein fragment was also recruited by GR-C108297. A fragment of corepressor 
NCoR1 only interacted after incubation with RU486. Asterisks indicate significant difference from the 
control condition (P < 0.001). 
substantial agonist effect of C108297 was observed for stress-induced CRH hnRNA in the 
PVN. This response was equally strongly suppressed by DEX and C108297 (figure 3C, 1-way 
ANOVA p < 0.001). In the CeA, the levels of CRH hnRNA were below detection, even after 
prolonged exposure of the films. Thus C108297 showed (partial) agonism in the PVN, but not 
in CeA. 
In order to assess other (ant)agonist-like effects of C108297 on HPA-axis activity, we 
determined basal and acute restraint stress-induced ACTH secretion after 5 days of treatment 
(figure 3D; 2-way ANOVA effects of time after onset of stress, drug-pretreatment (p < 0.001) 
and an interaction (p < 0.01)). DEX led to a complete suppression of basal and stress-induced 
ACTH release. Subchronic C108297 treatment did not affect basal ACTH levels in these ADX 
animals, but led to a modest suppression of stress-induced ACTH release, possibly indicating 




C108297 has selective antagonist activity in adrenally intact rats: In order to determine 
neuroendocrine antagonistic effects against endogenous corticosterone we compared 5-day 
treatment of C108297 (20 mg/kg) with RU486 (40 mg/kg) in adrenally intact rats, followed by 
restraint stress on day 5 in half of the animals. The stressor strongly induced expression of 
both CRH hnRNA in the PVN (2-way ANOVA p < 0.001) and led to a modest increase in 
CRH mRNA (2-way ANOVA p < 0.05), but these parameters were not affected by drug 
treatment (not shown), consistent with a lack of GR involvement in the immediate curtailing 
of the transcriptional CRH response in acute stress situations (27). There was no effect of 
subchronic drug treatment or the stressor on amygdala CRH mRNA. The only central measure 
that responded to subchronic drug treatment in intact rats was the c-fos response to restraint-
stress in the PVN (1-way ANOVA p < 0.001). Both RU486 and C108927 treatment led to 
elevated c-fos mRNA expression 30 min after the onset of stress (figure 4A).  
With regard to stress-induced activation of the HPA-axis, the two compounds also led to 
similar changes, indicative of antagonism by C108297. At 15 min after the onset of the 
Figure 3. Selective GR modulation in the stress system. C108297-agonism in ADX rats after subchronic 
treatment compared with the prototypic agonist DEX.  A. In the PVN, where SRC-1A is expressed at 
high levels, DEX led to strong down-regulation of CRH mRNA (P < 0.001). C108297 had a modest 
agonist effect that reached significance in the stressed group (P < 0.05).  B. In the CeA, DEX up-
regulated CRH mRNA in nonstressed rats (P < 0.05), but C108297 was without effect.  C. The acute 
response of the Crh gene in response to restraint stress was strongly attenuated both by pretreatment with 
DEX and C108297.   D. DEX led to a complete blockade of the HPA axis (P < 0.001), whereas C108297 
leads to a very weak attenuation of the adrenocortical stress response (P < 0.05). 
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restraint stress, corticosterone levels were about 25% lower in both the RU486 (301 ± 69 ng/
ml) (28) and C108297 (273 ± 52 ng/ml) treatment groups, compared to controls (409 ± 36 ng/
ml). In contrast, RU486 increased the amplitude of the basal diurnal corticosterone rhythm by 
increasing evening corticosterone levels without affecting AM levels, as described (9), but 
C108297 did not have this antagonistic effect (figure 4B, p < 0.001 for drug, time and 
interaction effects).  
 
Agonism and antagonism on neurogenesis and behavior: In order to further evaluate the 
efficacy of C108297 in animal models with relevance for psychopathology, we evaluated the 
effect of C108297 in two paradigms: corticosterone-induced suppression of neurogenesis, and 
memory consolidation of inhibitory avoidance training. 
C108297 was tested for reversal of GR-dependent reduction in adult neurogenesis after 3 
weeks of treatment with a high dose of corticosterone (40 mg/kg/day). RU486 was earlier 
shown to fully normalize the reduction in neurogenesis induced by corticosterone or chronic 
stress (29). In a comparable design, C108297 (50 mg/kg) was administered during the last four 
days of corticosterone treatment. Two-way ANOVA indicated that the number of cells that 
stained for BrdU (a marker for newborn cell survival) was affected by chronic corticosterone 
treatment (p = 0.008) and by C108297 treatment (p < 0.001), but there was no significant 
interaction. Post-hoc analysis revealed that the difference between C108297 and vehicle 
groups only reached significance in animals treated chronically with corticosterone (figure 
5A). The number of doublecortin (DCX) positive cells in the dentate gyrus, indicative of 
neuronal differentiation of newborn cells, was affected by chronic corticosterone treatment (p 
= 0.002), but not by C108297 (p > 0.4), although there was a trend towards an interaction (p = 
0.089). Post-hoc analysis indicated a significantly lower number of DCX positive cells after 
chronic corticosterone treatment only in the group treated with the vehicle for C108297 (figure 
5B). Thus, C108297 partially counteracted the effects of chronic corticosterone treatment. 
Figure 4. Selective GR modulation in the stress system: antagonism in adrenally intact rats after 
subchronic treatment compared with the prototypic antagonist RU486.  A. The acute c-fos response to 
stress in the PVN was enhanced both by pretreatment with RU486 and C108297.  B. RU486 treatment 





To determine whether C108297 affected memory consolidation, rats were trained on an 
aversively motivated single-trial inhibitory avoidance task, which is known to be potentiated 
by GR activation (30). A corticosterone (1 mg/kg) treatment was included as a positive 
control. Retention test latencies, as assessed 48 h after training, indicated a significant drug 
treatment effect (Kruskal-Wallis test, p < 0.001, figure 5C). Rats treated with either 
corticosterone or C108297 had significantly longer retention latencies than vehicle-treated 
rats (p < 0.001). This effect could be blocked by RU486 pretreatment. These findings indicate 
that C108297 has substantial GR agonism in this paradigm. 
Figure 5. C108297 acts as GR antagonist in neurogenesis and as agonist in memory retention. A. 
Chronic corticosterone suppressed the number of BrdU positive cell, and 4 d of C108297 treatment 
increased this number. BrdU scores were significantly higher in animals that received C108297 in 
combination with chronic corticosterone, compared with corticosterone-treated animals that did not 
receive C108297.  B. Total DCX-positive cells were significantly fewer after 3 wk of corticosterone 
treatment but not in animals that also received C108297.  C. Acute posttraining C108297 (20 mg/kg) or 
corticosterone (1 mg/kg) led to long 48-h retention test latencies in the inhibitory avoidance task, and 
these effects were blocked by pretreatment with RU486. Significant differences: *P <0.05; **P < 0.01; 







High levels of circulating glucocorticoids as a consequence of acute or chronic stress are 
known risk factors in the development of psychopathologies, either as predisposing factors or 
during precipitation of disease. GR antagonists have therapeutic potential (28, 31), but given 
the ubiquitous expression of the GR they have many undesired side-effects (32). Disinhibition 
of the HPA-axis is a side effect that actually counteracts the goal of any such treatment (i.e. 
blockade of GR signaling). SGRM compounds that combine antagonistic and agonistic GR 
properties may lead to a better-targeted interference with stress-related brain processes.  
Based on the C108297-induced interactions between GR and its coregulators, we 
hypothesized and confirmed that this compound is a selective GR modulator, with relevance 
for the brain. Interestingly, clear antagonist effects on the brain were accompanied by lack of 
negative feedback inhibition of the HPA-axis, which in itself suggests the possibility of 
antagonizing a number of GR effects without affecting systemic basal glucocorticoid levels, 
and the associated change in activity of, for example, mineralocorticoid receptor-dependent 
processes (33). C108297 is expected to have selective modulator effects also in peripheral 
tissues that we did not examine here (34). We did not determine binding to MR and PR or 
specific MR/PR readouts here, but previous studies showed 0% displacement from MR and 
26% from PR at 10 µM C108297, i.e. over a 1000-fold selectivity for GR (18). In peripheral 
tissues we cannot exclude some binding to PR with the 20 mg/kg dose C108297, but under 
non-saturating conditions for brain GR, activation of other steroid receptors is unlikely.  
Selective targeting to the brain may constitute a particularly efficacious way to interfere with a 
number of central GR-dependent processes, with very few side effects.  
In the MARCoNI assay the overall strength of the GR bound to C108297 interactions with 
coregulator motifs is somewhat lower than for GR bound to DEX, suggesting that C108297 is 
a partial agonist. Some of the antagonist effects that we observed after a single dose in vivo 
may indeed reflect partial agonism relative to circulating corticosterone. However, because 
some of the coregulator interactions become zero while others still reach substantial levels, the 
molecular profile is that of a selective modulator. It is unclear at this point, whether the GR 
follows a two-state agonist conformation, with C108297 leading to a similar conformation to 
DEX, but less stable (35), or whether C108297 leads to a unique conformation of the GR-
LBD. C108297 clearly differs from the well-known (but non-selective) antagonist RU486, as 
it lacks the capacity to induce interactions with domains from corepressors NCoR and SMRT, 
and the associated intrinsic (repressive) activity that may come from those interactions (19).  
Reversal of glucocorticoid-induced effects was observed for expression of the Drd1a gene in 
the hippocampus. This effect may be of relevance for reversal of negative effects of 
glucocorticoids on cognition (36). Given chronically C108297 also antagonized the effects of 
corticosterone on adult neurogenesis. Here, C108297 seemed to be less potent than RU486 
(31), perhaps because of a lack of interactions between GR and the classical corepressors. 
Notwithstanding, reversal of decreased neurogenesis may be relevant for antidepressive 




effects in the context of stress-related psychopathology, as was predicted by its interactions 
with the coregulator SRC-1 splice variants (16, 17). The compound lacked efficacy for the 
potentially anxiogenic induction of CRH via GR (38) even in ADX rats. It showed a mild 
degree of agonism on basal CRH expression in the PVN, and pretreatment had a substantial 
suppressive (agonistic) effect on stress-induced CRH transcription (39). Moreover, there was 
a clear lack of antagonism by C108297 on basal regulation of the HPA axis, which is an 
important advantage over complete antagonists like RU486 when trying to interfere with 
central consequences of hypercorticism (9).  
C108297 does not cause an overall dampening of brain stress responses. Like RU486, it 
enhanced stress-induced neuronal activity in the PVN, either indicating changed 
responsiveness of the parvocellular neurons, or changed activity of neuronal afferents to the 
PVN. The apparent agonism on BDNF expression (21) also shows that some consequences of 
stress may be mimicked by the compound. The GR-dependent increased consolidation of 
inhibitory avoidance memory also is in line with well-known stress effects, and can be either 
adaptive or maladaptive (6, 40).  
Our data emphasize the multiple levels of GR-mediated control over the HPA-axis. For 
example, RU486 as well as C108297 led to an increased c-fos response to stress in the PVN, 
but to an attenuated stress-induced ACTH release. This dissociation has been observed by 
others after direct and acute manipulation of the PVN (41). The extent to which CRH and c-
fos respond to stressors in ‘naïve’ rats is in general highly dependent on multiple factors, 
including the type of stressor and time after stress (42, 43). 
A small part of the selective GR modulation in vivo may be explained by differential 
recruitment of SRC-1A and 1E, and the role of numerous GR-coregulator interactions in 
mediating the many effects of GR activation on brain will be subject to further research. 
SGRMs such as C108297 and their molecular interaction profiles, combined with knowledge 
of the regional distribution of coregulators in the brain, can in future assist in dissecting the 
molecular signaling pathways underlying stress-related disorders. In fact, although our 
analysis was necessarily not comprehensive (e.g. in relation to non-genomic GR signaling 
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Supplementary figure 1. C108297 and RU486 45’ before the stressor lead to reduced corticosterone res-
ponse to a 0.4 mA footshock. Two way ANOVA show main effects of time and drug, but no interaction. 
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Blockade of glucocorticoid effects may be relevant for various disease conditions 
characterized by excess of glucocorticoid levels, such as Cushing’s disease and psychotic 
depression. However, classical antagonists such as RU486, which also binds the progesterone 
receptor (PR), may not be sufficiently selective for the glucocorticoid receptor (GR). In 
addition, RU486 may lead to disinhibition of the HPA axis, thus resulting in higher 
glucocorticoid levels that counteract its antagonism. Here we investigated the functional 
profile of a novel selective GR ligand (C118335). C118335 does not bind to the PR, but 
retains modest affinity for the mineralocorticoid receptor. Our results showed that C118335 
induced a unique GR-coregulator interaction profile with preferential recruitment of the 
Steroid receptor coactivator-1a nuclear receptor box. C118335 antagonized the effects of 
corticosterone on SGK-1 and FKBP5 expression in the CA1-CA2 region of the hippocampus 
and attenuated memory consolidation in an inhibitory avoidance test. Finally, we did not find 
disinhibition of the HPA axis after treatment with C118335. In conclusion, we offer here a 
proof-of-principle for the efficacy of this compound, which shows a more selective 






Orchestration of appropriate responses to stressors is indispensable for survival. In 
neuroendocrine realm such responses are largely mediated by the HPA axis and 
glucocorticoids (1, 2). However, if glucocorticoid responses are excessive or prolonged, 
vulnerability to psychopathology is enhanced (e.g major depressive disorder) (1). In such 
cases, antagonism of the glucocorticoid receptor (GR) may be of therapeutic interest (3). GR 
shows a widely distributed expression pattern and is involved among others in neuroendocrine 
negative feedback regulation (4) and learning and memory processes (5, 6). 
In order to mediate glucocorticoid effects on transcription, the GR, similarly to other nuclear 
receptors, needs to interact with other proteins, among which several classes of  transcriptional 
coregulators. To date, several hundred coregulators that interact with nuclear receptors have 
been discovered. They differ in their expression patterns in the brain, as well as in their 
affinity for different ligand-bound nuclear receptors (7). The differences in expression patterns 
of nuclear receptors and coregulators in different brain tissues may be the basis for the gene- 
and tissue-specific effects of glucocorticoids that are often observed in different contexts (8, 
9). This variability of nuclear receptor-coregulator interactions may also offer a new approach 
for neuropharmacological intervention in psychopathology.  
Due to the pleiotropic effects of cortisol and corticosterone on diverse processes, full 
antagonism may not always be desirable, as it may block the pathogenic as well as the 
beneficial effects of these naturally occurring glucocorticoids. Moreover, the classical GR 
antagonist RU486 is not specific for the GR, but can also bind the progesterone receptor (PR), 
resulting in serious adverse effects (10). Finally, full GR antagonism also blocks the negative 
feedback loop of the HPA axis, thus resulting in even higher levels of circulating 
glucocorticoids, which may still exert effects via the other receptor of glucocorticoids in the 
brain, the mineralocorticoid receptor (MR) (11, 12). Therefore, there have been continuous 
attempts to develop ligands with the highest possible specificity for GR that can also target 
specific GR-dependent pathways (13-16). 
Here, we investigated the effects on the brain of a novel GR ligand (C118335) that shows 
selectivity for GR over AR and PR, but with modest affinity for MR (17). We studied the 
effects of this compound on SGK-1, BDNF and FKBP5 expression in the CA1-CA2 region of 
the hippocampus and the dorsal striatum, stress-related behavior and regulation of the HPA 
axis. Gene selection was based on known GR-targets and on the involvement of these genes in 
GR signaling. We found that C118335 had antagonistic effects on glucocorticoid-induced 
SGK-1 and FKBP5 expression in the brain, and showed mild suppression of the HPA axis 
after stress. In line with the gene expression findings, it showed antagonistic effects on 








Peptide interaction profiling: Interactions between the GR ligand binding domain (LBD) 
and coregulator NR-boxes were determined on a MARCoNI assay. The method has been 
previously described, in detail, elsewhere (9, 18). Briefly, each array was incubated with a 
reaction mixture of 1 nM GST-tagged GR-LBD, ALEXA488-conjugated GST- antibody, and 
buffer F (PV4689, A-11131, and PV4547; Invitrogen, Bleiswijk, the Netherlands) and vehicle 
(2% DMSO in water), Dexamethasone (DEX; 1 μM), RU486 (1 μM), or C118335 in various 
concentrations. Incubation was performed at 20 °C in a PamStation96 (Pamgene International, 
Den Bosch, the Netherlands). GR binding to each peptide on the array, reflected by 
fluorescent signal, was quantified by analysis of .tiff images using BioNavigator software 
(Pamgene International). 
Animals: 10-14 week old male Sprague-Dawley rats were used. The rats were group housed 
with food and water available ad libitum under a 12:12 dark:light regime. For gene expression 
studies, 5-7 rats per group were injected subcutaneously with vehicle (90% PEG, 10% 
DMSO), C118335 (100 mg/kg), followed 30 mins later by an injection of corticosterone (3 
mg/kg) or vehicle. Three hours after the second injection animals were sacrificed by an 
intraperitoneal injection of overdose Euthasol (ASTfarma, Oudewater, the Netherlands) 
followed by decapitation. Their brains were harvested and snap frozen in isopentane on dry ice 
and subsequently stored at -80 oC. Trunk blood was also collected in EDTA coated tubes, 
centrifuged and plasma collected and stored at -20 oC until further processing. All experiments 
were carried out in accordance with the European Community Council Directive of November 
24, 1986 (86/609/EEC) and experiments were approved by the Local Committees for Animal 
Health, Ethics, and Research of the Dutch universities involved (DEC protocol: 12167). 
Radioimmunoassay: Plasma corticosterone levels were determined with Radioimmunoassays 
using 125I RIA kits (MP Biochemicals, Santa Ana, CA, USA) as per the manufacturer’s 
instructions.  
Punching: 200 μm thick sections were taken on a Leica 3050 cryostat (Rijswijk, the 
Netherlands) and mounted on uncoated glass slides (Menzel-Gläser, Braunschweig, 
Germany). Subsequently tissue was punched out from the caudate putamen  and the CA1-CA2 
region of the dorsal hippocampus using appropriate Harris Uni-core punching needles 
(Tedpella, Redding, CA, USA). 
RNA isolation, cDNA synthesis and qPCR: The samples were homogenized on a 
TissueLyser II (Retsch Qiagen, Haan, Germany) in 1 ml Trizol, centrifuged and 200 µl of 
chloroform (Merck KGaA, Darmstadt, Germany) was added to each sample. After 
centrifugation, the aqueous phase (top phase) was taken and 5 µl of 5 mg/ml linear acrylamide 
(Ambion, Austin, USA), as a carrier, and 500 µl isopropyl alcohol (Merck KGaA, Darmstadt, 
Germany) were added, followed by centrifugation and removal of the supernatant. Then, the 
RNA pellet was washed twice with 75% ethanol (Merck KGaA, Darmstadt, Germany), air-
dried and dissolved in demineralized H2O. The purity and concentration of the RNA samples 
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were measured on the Nanodrop 1000 (Isogen Life Science, De Meern, The Netherlands). The 
integrity of the samples was measured on Standardsens chips on a Bio-Rad experion system 
(Hercules, USA). 
For cDNA synthesis, RNA samples were pretreated with DNase (Promega, Madison, USA) to 
remove potential genomic DNA contamination according to the manufacturer’s specifications. 
For the incubation a MyCyclertm Thermal Cycler (Bio-Rad, Hercules, USA) was used. 
Subsequently, cDNA was synthesized with iScript cDNA Synthesis Kit (Bio-Rad). Four µl 5x 
iScript reaction mix, 1 µl iScript reverse transcriptase (RT) and 5 µl nuclease free water were 
added to each DNase pretreated sample. A control sample without RT treatment was also 
included in which the 1 µl RT was replaced by 1 µl nuclease free water. The samples were 
placed in a MyCyclertm Termal Cycler and incubated for 5 minutes at 25oC, 30 minutes at 
42oC and 5 minutes at 85oC (11).  
Quantitative polymerase chain reaction (qPCR) was performed to measure gene expression in 
the different brain regions. The efficiency of the used primers was first measured for each 
gene in each region. To perform the qPCR the FC FastStartDNA Masterplus SYBR Green I 
(Roche Applied Science, Basel, Switzerland) kit was used. 2.5 µl per cDNA sample was added 
to a mix of 2 µl 5x Sybr green mix, 0.5 µl 10 µM of both the forward and reverse primers 
(table 1) and 4.5 µl DEPC H2O to a total volume of 10 µl. For the reactions 20 µl LightCycler 
Capillaries (Roche) were used placed in a LightCycler Sample Carousel 2.0 (Roche). The 
carousel was centrifuged on a LC Carousel Centrifuge 2.0 (Roche), subsequently placed in a 
LightCycler 2.0 (Roche) to perform qPCR. All samples were measured in duplicate. The 
samples were incubated for 10 minutes at 95oC, followed by 45 replication cycles (10 seconds 
denaturation at 95oC, 10 seconds annealing at 60oC and 10 seconds elongation at 72oC) and 
finally a melting curve was made (65oC to 95oC, 0.1oC/s).  
Inhibitory avoidance: One-trial inhibitory avoidance training and retention was performed as 
has been described elsewhere (19), using single-housed male Wistar rats (10-14 weeks of age; 
Charles River) and a foot-shock intensity of 0.38 mA for 1 s. C118335 (20 or 80 mg/kg) or 
corticosterone (1 mg/kg) was dissolved in DMSO and administered (100 μl, s.c.) immediately 
after the training trial, to prevent interference with memory acquisition. Retention was tested 
48 h later. A shorter latency to enter the former shock compartment with all four paws 
(maximum latency of 600 s) was interpreted as weaker memory. 
Statistical analysis: To analyze the levels of Cort in the trunk blood a t-test with a 
significance level of P<0.05 between the vehicle and the C118335 treated group was used. In 
order to determine whether treatment with corticosterone increased the corticosterone-
circulating levels a two-way ANOVA was used.  For the analysis of the Ct values from the 
qPCR the mathematical model from Pfaffl (20) was used. Tubulin and ACTB were used as 
reference (housekeeping) genes. The geometric mean of these two genes was used as the 
reference value. The Grubbs’ outlier test was conducted and outliers were excluded from the 
analysis. The values were analysed by one-way ANOVA followed by Tukey’s post-hoc test 
with a significance level of P<0.05. In the inhibitory avoidance test the Kruskal-Wallis test 




Figure 1. C118335  did not induce as many GR-LBD – coregulator peptide interactions as 
dexamethasone. However, it induced partial recruitment of the SRC-1a specific NR box-IV (NCOA1-
1421-1441). A. Overview of the ligand-induced interactions between GR-LBD and coregulator motifs 
after treatment with DMSO, the classical antagonist RU486, the novel GR ligand C118335 and 
dexamethasone. B. C118335 induced GR-LBD – SRC-1 NR-box IV interactions in a dose-dependent 
manner, while it did not induce considerable GR-LBD- SRC-1 NR-box I (NCOA1-620-643) interactions 
at any concentration. C. C118335 induced significantly stronger interactions between GR-LBD and SRC
-1 NR-box IV than DMSO, though not as strong as the dexamethasone induced interactions (one-way 
ANOVA, p<0.0001, F(3,15) = 168.6, tukey’s post hoc test: ***, p<0.001 compared to DMSO group; #, 
p<0.001 compared to RU486 group. D. C118335 did not induce SRC-1 NR-box I –GR-LBD interaction, 
unlike dexamethasone: One-way ANOVA: p<0.0001, F(3,15)= 227.6, tukey’s post-hoc test: ***, p <0.001 
compared to DMSO group, #, p<0.001 compared to RU486 group, $, p<0,001 compared to C118335 
group. E. C118335 did not induce interactions with the corepressor motif NCOR1-2251-2273 : One-way 
ANOVA : p< 0.0001, F(3,15) = 16.89, tukey’s post hoc test: ***, p<0.001 compared to DMSO group; #, 
p<0.001 compared to RU486 group. 






C118335 induces a unique GR-LBD – coregulator interaction profile: C118335 generally 
did not induce as many interactions as dexamethasone (Figure 1a). However, it selectively 
recruited a number of NR boxes, such as the SRC-1 NR-box IV in a dose-dependent manner 
(Figure 1b, c), but to a lesser extent than dexamethasone (Figure 1c). On the other hand, 
C118335 did not induce interactions between the GR-LBD and SRC-1 NR-box I, unlike 
dexamethasone (Figure 1d) and in contrast to RU486, it did not recruit corepressor motif 
NCOR1 2251-2273 (Figure 1e). This suggests that the compound will act as an antagonist on 
most processes that depend on the coregulators represented at the array, but may show 
substantial partial agonism for others. 
Trunk blood corticosterone levels: Animals treated with C118335 had significantly lower 
corticosterone plasma levels than controls (Figure 2a). As expected corticosterone-treated 
animals had higher corticosterone plasma levels than the respective control treated groups 
(Figure 2b). Of relevance for the interpretation of the gene expression data, vehicle animals 
also had relatively high levels of plasma corticosterone. 
C118335 attenuates the corticosterone-induced upregulation of FKBP5 and SGK-1 but 
enhances BDNF expression, in the CA1-CA2 region of the hippocampus: Treatment with 
corticosterone in the absence of other ligands resulted in a strong upregulation of FKBP5 
expression in the CA1-CA2 region of the hippocampus. Treatment with C118335 resulted in 
suppression of the corticosterone-induced FKBP5 upregulation (Figure 3a). Similarly, 
Table 1. Primer sequences used for qPCR analysis and the expected product sizes.  
 Name 
 Forward Primer (5’-3’)
  
 Reverse Primer (5’-3’) 





























Figure 2. A. Endogenous corticosterone levels after treatment with vehicle or C118335. Rats treated with 
C118335 had lower plasma corticosterone levels compared to vehicle (two-tailed t-test: t(10)=2.346, 
p=0.04). B. Two-way ANOVA reveled a Glucocorticoid treatment effect, where treatment with 
corticosterone increased circulating corticosterone plasma levels ( F(1,21) = 14.71, p=0.001). N = 5-6 per 
group. Bonferroni post-hoc test: ***, p<0.001. No Compound effect was found in this analysis. 
Figure 3: FKBP5 and SGK-1 expression in the hippocampus. A. C118335 can block the corticosterone-
induced upregulation of FKBP5 in the hippocampus. There was a significant Glucocorticoid treatment 
effect (F(1,20) = 16.56, p<0.001), a significant  Compound treatment effect (F(1,20) = 16.23, p<0.001) and a 
significant Glucocorticoid X Compound interaction (F(1,20) = 7.301, p< 0.05). B. C118335 downregulated 
SGK-1 expression in the hippocampus regardless of glucocorticoid treatment. A compound effect was 
observed (F(1,20) = 25.71, p<0.001) and a marginally non-significant interaction effect (F(1,20) = 4.127, 
p<0.06). Bonferroni post-hoc test, ***, p<0.001, n=5-6 per group. 
C118335 resulted in decreased expression of SGK-1 regardless of glucocorticoid treatment in 
these adrenally intact animals (Figure 3b). C118335 increased BDNF expression in the 
hippocampus, but this effect was blocked by corticosterone treatment (Figure 4).  
C118335 attenuates the corticosterone-induced upregulation of SGK-1 in the striatum, 
but it had no effect on FKBP5: C118335 had no effect on FKBP5 expression (Figure 5a). 
However, SGK-1 expression was upregulated in the striatum after treatment with 





Figure 5: SGK-1 expression in the striatum. A. No Compound effect was found on FKBP5 expression in 
the striatum (F(1,21)=0.003, p>0.95.  However, a trend towards a Glucocorticoid treatment effect was 
found (F(1,21)=3.274, p=0.084). B. C118335 treatment prevented the corticosterone-induced upregulation 
of SGK-1. There was a significant Glucocorticoid treatment effect (F(1,20) = 8.197, p<0.01) and a 
significant Compound effect (F(1,20) = 8.295, p<0.01. 
Figure 4: C118335 had effects on BDNF expression in the hippocampus.  C18335 treatment resulted in 
upregulation of BDNF expression, but this effect was blocked by treatment with glucocorticoids. A 
significant Glucocorticoid treatment effect was found (F(1,20) = 5.093, p<0.05. The Compound effect 
was marginally non-significant (F(1,20) = 4.286, p = 0.052). Bonferroni post-hoc test: *, p<0.05, n=5-6 
per group. 
C118335 resulted in decreased memory consolidation in an inhibitory avoidance test: To 
determine the effect of C118335 on stress-related behavior we used an inhibitory avoidance 
paradigm. In order to examine the potential dose responsiveness, we used two doses of the 
compound (20 and 80 mg/kg). Our results showed that immediate post-training treatment with 
C118335 resulted in decreased latency to enter the dark compartment in testing two days later 
only when the higher dose was administered. Treatment with 20 mg/kg C118335 had no effect 







Blocking the undesired effects of glucocorticoids, in both the brain and the periphery, may be 
of relevance for a number of conditions such as Cushing’s disease and psychotic depression 
(21-24). However, the available antagonists are, however, not specific for GR and their use 
may be accompanied by adverse effects that decrease their therapeutic potential. RU486, for 
instance, binds also the progesterone receptor and can induce abortion. Moreover, it disinhibits 
the HPA axis resulting in even higher cortisol levels, thus counteracting its effects (25). 
Therefore, it is necessary to search for more specific GR ligands in order to minimize potential 
side effects. 
A possible level of regulation of nuclear receptor function arises from modulation of nuclear 
receptor-coregulator interactions (7). Recently, we characterized the selective GR modulator 
C108297 in a wide array of tests (9). This compound behaved both as agonist and antagonist 
depending on the context and brain region. Its effects were, at least to some extent, attributed 
to the unique profile of GR-coregulator interactions it could induce (9). 
In this study we investigated the effects of the novel GR ligand C118335 on glucocorticoid 
dependent gene expression in vivo and on fear memory consolidation in an inhibitory 
avoidance test. In contrast to RU486, this compound does not bind to the progesterone or the 
androgen receptor, but it retains some affinity for the MR (17). Our findings suggest a strong 
antagonist profile of C118335, both in gene expression and inhibitory avoidance. 
Interestingly, however, treatment with C118335 did not disinhibit the HPA axis. 
Figure 6: C118335 showed an antagonist effect in an inhibitory avoidance test only at a higher dose (80 
mg/kg). The lower dose of 20 mg/kg did not have an effect on the consolidation in the inhibitory 
avoidance test (Kruskal-Wallis test, Kruskal-Wallis statistic =18.63, p<0.001, n=9-11 per group, ***, 
Dunn’s post-hoc test, p<0.001). 
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C118335 induced only a modest subset of the dexamethasone-induced GR-LBD - coregulator 
interactions, with about 50% efficacy for the strongest interactions. Interestingly, however, it 
recruited the SRC-1a specific NR box (SRC-1 NR-box IV) in a dose-dependent manner. SRC-
1a potentiates repression of crh promoter activity in vitro (26), while it may also be necessary 
for appropriate crh expression regulation by glucocorticoids in the PVN, as well (8). In the 
current study using adrenally intact rats it is not possible to discriminate between pure 
antagonistic effects and partial agonism relative to endogenous corticosterone. In contrast to 
RU486, C118335 did not recruit any corepressor motifs. This suggests differences in the mode 
of action of C118335 compared to RU486 and the lack of corepressor recruitment may prevent 
the abrogation of all GR-mediated effects, thus it may lack some of the RU486-associated 
adverse effects.  
Despite the high corticosterone plasma levels of the vehicle group in the present study, 
additional exogenous corticosterone treatment further increased the corticosterone levels and 
this increase was accompanied by induced changes in gene expression in the brain. On the 
other hand, the high corticosterone levels may have masked potential agonistic properties of 
C118335. C118335 treatment resulted in blockade of corticosterone-induced upregulation of 
FKBP5 and SGK-1. Both genes are GR-target genes, but also play an important role in 
mediation of the transcriptional effects of GR. SGK-1 may prolong the GR effects even in the 
absence of glucocorticoids, while it has been found increased in depressed patients (27). Here 
we found downregulation of SGK-1 expression below basal levels, which may be indicative of 
an effect at two levels: a direct effect on SGK-1 expression regulation by GR and an indirect 
effect on transcriptional activity due to decreased SGK-1 expression (27). On the other hand, 
FKBP5 may have inhibitory activity on GR function and it is involved in the ultrashort 
intracellular negative feedback loop of GR activity (28, 29). Although these two target genes 
exert opposite actions on GR signaling, the fact that the corticosterone-induced upregulation of 
both was blocked may indicate an overall dampening of the transcriptional effects of GR. 
Nevertheless, SGK-1 and FKBP5 may also be regulated in a brain region-specific fashion, 
thus making predictions of the net GR-dependent transcriptional outcome difficult. 
BDNF is another gene regulated by glucocorticoids (30-32), also involved itself in GR 
signaling (32-35).  C118335 treatment upregulated BDNF expression in the hippocampus, 
however, it was not enough to counteract the effect of higher corticosterone levels. The lack of 
efficacy of corticosterone treatment may reflect the relatively high endogenous corticosterone 
levels, which may have led to low BDNF expression levels (9, 36). The observed upregulation 
of BDNF expression in the hippocampus may be of relevance for psychopathology, as similar 
effects have been reported after treatment with antidepressants in rodents and humans (37-39). 
The effects on glucocorticoid levels may be explained by the effects of C118335 on GR-
coregulator interactions. C118335 preferentially recruited the SRC-1a-specific NR-box. SRC-
1a potentiates the repression of the crh promoter and may be involved in the regulation of 
CRH expression by glucocorticoids in the PVN by the GR (8, 26). Interestingly, in studies in 
SRC-1 KO mice it has been shown that SRC-1 is involved in negative feedback of the HPA 
axis at the pituitary and the PVN (8, 40). Considering the relative abundance of the two SRC-1 




this is relevant (and to which extent) in conditions of chronic stress or prolonged 
hypercortisolemia.  
There was a clear antagonist effect of C118335 on fear memory consolidation in an inhibitory 
avoidance test. This was in line with previous findings, as immediate post-training GR 
antagonism has been shown to interfere with memory consolidation. The considerable effect 
of C118335 treatment observed here may also be related to the downregulation of SGK-1 
expression below basal levels. Finally, the expected weak antagonism on MR may also be 
relevant to the effects of C118335 on memory consolidation. 
In conclusion, we offer here a proof-of-principle for the efficacy of a novel GR antagonist 
which, in contrast to RU486, does not bind the progesterone receptor and induces a distinct 
GR-LBD – coregulator motif interaction profile. Therefore, C118335 may have an interesting 
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The appropriate orchestration and expression of responses to stressors is crucial for survival 
and involves the coordination of multiple systems in the brain and the periphery (1-4). The 
HPA axis plays a central role in the regulation of stress responses via control of glucocorticoid 
hormone levels. Glucocorticoids, in turn, exert a wide range of effects, including effects on 
memory, behavior and metabolism, that are mediated by their receptors MR and GR. 
Importantly, glucocorticoids can block the expression of CRH in the PVN and ACTH in the 
pituitary, thus controlling their expression via a negative feedback loop (5, 6). 
Due to their coordinating effects, the function of GR and MR must be tightly regulated in a 
tissue-specific fashion rather than simply follow the changes in concentration of their ligands 
in a uniform way. This tissue-specific regulation may take place at multiple levels, such as the 
expression of the receptor, the bio-availability of free ligand in plasma, the expression of 
enzymes that modify the ligand, the expression of other nuclear receptors, the presence of 
other transcription factors and the expression and availability of coregulators (4).  The latter, 
may create a bottleneck, as competition of nuclear receptors for coregulators may be the 
limiting factor when multiple signals are received at the same time.  
Several coregulators have been shown to be important for brain function and particularly for 
learning and memory and stress responses. Notable examples, apart from SRC members of the 
p160 family, are the coregulators of CREB CBP/p300 and pCAF, members of the CREB 
regulated transcription coactivator (CRTC) family, the coregulators of steroid hormone 
receptors RIP-140, Ube3a and proteins involved in the SWI/SNF chromatin remodeling 
complex (7-20). Not surprisingly, mutations or deletions of these coregulators often result in 
impairments in learning and memory, decreased neuronal plasticity, inappropriate regulation 
of stress responses or abnormal brain morphology (21). 
Here, we studied the importance of coregulator recruitment in relation to stress and effects of 
glucocorticoids in two different ways: First, we tried to manipulate the sensitivity of the 
central amygdala to glucocorticoids and interfere with proper stress responses, via induction 
of alternative splicing of the well-described coregulator and member of the p160 family SRC-
1. Secondly, with the use of novel selective ligands of the GR we tried to interfere with GR-
coregulator interactions and selectively block a subset of GR-dependent functions while 
leaving others intact. Subsequently, we studied the effects of these ligands on stress-induced 
CRH expression, fear-related memory consolidation and GR-dependent gene expression in the 
brain in vivo.  
 
SRC-1 isoform switching in the CeA 
First, we showed that AON-mediated exon skipping in the CeA is a feasible technique to 
modulate splicing of the NCoA1 gene (22). We compared the immunostimulatory potential of 
a random 2-O’-Me ribonucleotide with a phosphorothioate backbone, which had no known 
targets in the murine genome or transcriptome, to saline. Our results showed no differences 
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between treatments in any of the markers of astrogliosis or microglia activation we used. 
Previous studies using similar concentrations of AONs as in our study, also reported no 
immunogenicity, although this might be the case for higher AON concentrations (23). In fact, 
the 2-O’modification used in the design of the AON may have acted as a Toll-like receptor 
antagonist, thus decreasing potential immunostimulatory effects (24, 25).   
Secondly, we showed adequate uptake of the AONs from neurons and localization of the 
AONs in the cell nuclei. Both findings were important, because they indicated success in 
transfecting the desired cell type and cell compartment, although the underlying mechanism 
remains largely unknown ((26) for an overview of theories that have been proposed regarding 
the cellular uptake and intracellular trafficking of AONs), it is important that they are taken up 
and end up in the nucleus, since splicing takes place in the nucleus. Therefore, for any 
experimental or therapeutic effect of the AONs, this condition should be met. 
Finally, we showed that a single injection of AONs targeting the SRC-1e specific exon in the 
CeA could result in exon skipping and a shift in expression ratio of the two SRC-1 splice 
variants in favour of SRC-1a, three and seven days post- injection. The expression ratio shift 
was not accompanied by differences in the expression levels of total SRC-1, indicating that 
the effects were selective for the SRC-1e specific exon, leaving total expression levels intact. 
Taken together, our results showed that exon skipping may be an appropriate technique for 
interference with gene expression in the brain, either for experimental or therapeutic purposes. 
In our hands, it was characterized by specificity for SRC-1e, leaving total SRC-1 expression 
unaltered, as well as GR and SRC-2 expression, limited immunogenicity and high efficiency. 
Compared to siRNA methods or the use of viral constructs, it may offer the advantage of not 
causing cell death, since it does not use any intracellular machinery, thus it limits its 
interference with normal cellular functions (27, 28). 
The fact that AONs were still detectable and active seven days after a single injection may be 
useful for their applications as experimental tools, as it may be possible to avoid more 
invasive administration to the brain such as cannulation or repeated administration. Although 
this may still be necessary for longer experimental designs, for our purposes a single injection 
was sufficient to establish the desired SRC-1a:SRC-1e expression pattern throughout the 
experiment (23, 29).  
Considering that the majority of genes expressed in the brain undergo alternative splicing 
AON-mediated exon skipping has high potential (30). If one considers also the use of AON-
mediated exon skipping to selectively remove exons with known or unknown functions, thus 
leading to the expression of truncated proteins or internal deletions, the possibilities become 
endless. Similarly, alternative splicing may also be relevant for therapeutic interventions, 
either via splice variant selection or by restoration of the reading frame of mutated pre-mRNA 
molecules. Obviously, there are many more considerations before moving to human use such 
as safety, administration and efficacy; however, for some disease models AON-mediated exon 





Functional consequences of SRC-1 isoform switching in the CeA 
As the naturally occurring expression pattern of the two SRC-1 splice variants in the CeA 
favors SRC-1e (34), we sought to investigate what the effects of a shift of their expression 
ratio in favor of SRC-1a would be on the regulation of CRH expression by glucocorticoids as 
well as on stress-related behavior and fear memory. The CeA is an important area for the 
orchestration of appropriate responses to stressors and acquisition and expression of fear 
conditioning. GR signaling has been shown to be indispensable for those functions, as local 
knockdown of GR expression in the CeA results in fear conditioning impairments which can 
be rescued by ICV administration of CRH (35). In addition, GR knockdown in the CeA results 
in abrogation of CRH expression regulation by glucocorticoids (35). Moreover, it has been 
shown that SRC-1 expression in the CeA is necessary for proper regulation of CRH 
expression by glucocorticoids and normal basal CRH expression in the CeA (36). Finally, the 
two SRC-1 splice variants appear to have different effects on the regulation of the crh 
promoter; SRC-1a represses the crh promoter, whereas SRC-1e lacks repressive capacity (37). 
To test basal anxiety and consolidation of fear memory, we used two well-described 
paradigms: the open field and fear conditioning, respectively. Subsequently, we tested the 
effects on SRC-1 isoform switching on the regulation of CRH expression by glucocorticoids 
in the CeA. Our results suggested that a shift in expression ratio in favor of SRC-1a in the 
CeA leads to increased locomotion and impairments in a fear conditioning paradigm, as well 
as abrogation of CRH mRNA induction by chronic exposure to the synthetic glucocorticoid 
dexamethasone. These findings underline for the first time in vivo the importance of SRC-1 
for glucocorticoid signaling, as well as the differential effects of the two SRC-1 splice variants 
on the crh promoter. Interestingly, we found a positive correlation between the SRC-1a:SRC-
1e expression ratio and the total distance walked in the open field, which may indicate a direct 
relationship between the expression ratio of the two splice variants locomotor activity. 
The most striking effect was the complete blockade of the dexamethasone-induced CRH 
expression upregulation in the CeA after the expression ratio shift of the two splice variants. 
Here, it is important to emphasize the difference between the two SRC-1 splice variants in 
their affinity for the GR; the SRC-1a-specific NR box has higher affinity for the GR than the 
three central NR boxes (38). Thus, the effects of SRC-1a in the CeA may be amplified due to 
its higher affinity for the GR, rather than dependent on simple stoichiometry of the two splice 
variants. 
Another open question regards the cause of the observed behavioral differences. The fear 
conditioning results could be, at least to some extent, explained by the known effects of the 
two splice variants on CRH expression (36, 37). Kolber et al., showed that GR-dependent 
expression of CRH in the CeA is necessary for proper acquisition and consolidation of fear 
conditioning (35). However, we did not find differences in CRH expression after saline 
treatment (which are expected to be very close to basal levels), therefore, the differences in 
open field could not be easily explained in relation to CRH expression and function. Similarly, 
there were no differences in HPA axis reactivity at basal conditions or after stress. 
Importantly, basal CRH expression in the CeA may not be dependent on GR at all, as shown 
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by the modest effects observed after adrenalectomy (39). Considering the mode of action of 
coregulators, it is plausible that there are more GR-target genes differentially regulated by the 
two SRC-1 splice variants. To cast light to this issue further research is necessary employing 
broader gene expression analysis techniques such as mRNA microarrays or RNA sequencing 
to identify those “elusive” genes. In addition, given the interactions of coregulators with other 
nuclear receptors, such as the estrogen receptor (40), it would be useful to profile the 
interactions of the two SRC-1 splice variants with other coregulators or pathways of other 
transcription factors and nuclear receptors. For example, SRC-1 is known to interact with 
CBP/p300, a coregulator of CREB (41). CREB plays an important role in the activation of the 
CRH promoter, therefore, it would be essential to understand the extent of interplay between 
CREB- and GR-dependent transcriptional pathways and the role of the SRC-1 isoforms 
therein. 
In conclusion, splicing modulation and shifting of the expression ratio of naturally occurring 
splice variants may be of relevance for brain function. Furthermore, manipulation of 
downstream components of GR signaling may be of relevance for psychopathology, since they 
offer higher specificity than, for instance GR antagonism or GR knockdown. Finally, it 
suggests that SRC-1 and its splice variants may be possible targets for manipulation and of 
therapeutic relevance for psychopathology. 
 
Interactions of liganded GR with coregulators 
There is no comprehensive overview of the coregulators that interact with MR and/or GR. 
Moreover, for known coregulators, we have often little knowledge about the neuromodulatory 
actions in which they may be involved. The expression of all putative coregulators for MR and 
GR is available for both mouse and human in databases such as the Allen Brain Atlas (for a 
number of examples see: (42)). To interpret the expression data in a meaningful way, it is 
important to know which of the putative coregulators can interact with the receptors. The 
approach we used in chapters 4 and 5 to investigate the induced interactions by different 
ligands between the GR and a set of coregulators was the MARCoNI assay. This assay 
measures one-to-one binding of a given NR to a set of coregulators. The latter are represented 
as helical peptides of functional NR-box motifs, or their repressor protein equivalent (CoRNR-
box), selected from a broad base of literature. This set (>150) of peptides is immobilized in a 
micro-array format and NR binding is quantified using fluorescently labeled antibody (43). 
The NR-coregulator interaction profile serves as a sensor for receptor conformation and thus 
status of the AF-2 of the receptor (44). Functional modulation, e.g. by ligand, mutation or post
-translational modification of NRs, recombinant but also in whole-cell lysates (45) can hence 
be studied by quantification of coregulator interactions. Since this approach involves the use 
of only the LBD region, we lack relevant information regarding AF-1 (which may also be 
ligand independent (46)), interactions with other transcription factors (and transrepression 
activity mediated by them) (47), as well effects on non-genomic GR signaling (48). 
 
Assays like these will be of great assistance to identify relevant coactivators for individual 




expression data like those in the Allen Brain Atlas may bring us a long way to defining the 
coregulators that are involved in MR and GR signaling in particular brain regions. 
 
Targeting GR with novel GR ligands 
Besides targeting directly the expression or splicing of coregulators, it may be useful to 
modify the interactions between the GR and the coregulators that are present in a certain 
cellular context. In this regard, pharmacological modulation of the GR may be of particular 
interest both in the brain and the periphery. Classically, pharmacological manipulations were 
restricted to the use of agonists or antagonists. However, this approach has some limitations. 
The use of antagonists such as RU486, for instance in the treatment of the effects of 
hypercortisolemia, is characterized by some disadvantages which limit their therapeutic 
potential. One important issue is selectivity for the GR. RU486 binds also the progesterone 
receptor, thus acting as an abortifacient. There have been several attempts to design ligands 
with increased affinity for the GR compared to other receptors (49-51). The second important 
issue is that total GR antagonism may disinhibit the HPA axis, resulting in the elevation of 
glucocorticoid levels. In addition, it may not be desirable to block all GR-dependent effects, 
since some of them are beneficial for proper cognitive and memory functions. Hence, the use 
of selective GR ligands has been attempted to provide more specific modulation of the GR 
and block certain pathways while leaving others intact. These include attempts to develop GR 
ligands that retain their anti-inflammatory properties, without effects on metabolism (52-56). 
In chapter 4 we profiled the novel selective GR ligand C108297. We found that it induced a 
unique GR-coregulator interaction profile, resembling features of both agonists and 
antagonists. In particular, several GR-coregulator interactions were blocked, however, the 
SRC-1a specific NR box was preferentially recruited. On the other hand, there was no 
induction of GR-corepressor interactions. We also found mixed effects on gene expression in 
the brain with both agonistic and antagonistic effects. Notably, there was no disinhibition of 
the HPA axis, and we found agonistic effects on inhibitory avoidance but antagonism in the 
effects of corticosterone on adult neurogenesis. C108297 showed mild suppression of post-
stress CRH expression levels in PVN, but lacked any effects in the CeA. 
In chapter 5 we studied the effects of a novel GR ligand (C118335) on gene expression in the 
brain and inhibitory avoidance behavior. This compound induced in vitro a GR-coregulator 
interaction profile which resembled that of an antagonist, with some notable exceptions, such 
as the preferential recruitment of SRC-1 NR-box IV. Moreover, it was shown to be efficient 
against olanzapine-induced increase of body weight in rats, suggesting an RU486 like efficacy 
(57). We found that C118335 antagonized corticosterone-induced gene expression in the 
brain, and attenuated the consolidation of an inhibitory avoidance test. Interestingly, C118335 
did not disinhibit the HPA axis. Taken together, our data suggest that C118335 may be an 
improved GR antagonist compared to RU486. The two novel ligands that were tested showed 
distinct molecular interactions in the Marconi assay, which partly explained their in vivo 
efficacy. However, we are not able to predict the pharmacology of the compounds with a 
single assay, because the receptors can act via at least three distinct action mechanisms that 
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may be separately targeted. First, non-genomic signalling can take place either via membrane-
associated variants of the classical receptors (58, 59), or via cytoplasmic receptors (60). 
Second, transcriptional signalling can occur in a manner that depends on interaction with other 
transcription factors. AP-1 and NF-kB are well-known examples, but which interactions bear 
most relevance for the brain is mostly unknown (61). Thirdly, GR and MR can bind to the 
DNA in their classical GRE-dependent manner, and subsequently interact with any of tens of 
other transcription factors and coregulator proteins that constitute the actual signal 
transduction of the receptors. 
MR and GR always mediate hormone actions in a given cellular context – which may affect 
fear, memory, reward, or other aspects of cognitive and emotional processing, depending on 
the demands on the organism. The receptors do so via cross-talk with other signalling 
cascades that are activated, for instance, by glutamatergic or noradrenergic excitatory input. 
Much of the cross-talk may take place at the level of transcriptional coregulators that are 
common to the signal transduction of MR/GR and the cAMP-coupled transcription factor 
CREB (41).  Furthermore, cross-talk may also take place at the DNA level, either by one 
factor pioneering the binding site of another, or by binding to the same coregulator or 
transcription factor (46, 62). 
In order to make progress, basic knowledge of possible coregulators of MR and GR can be 
combined with the comprehensive expression databases that are available. The first reports on 
genome-wide DNA targets by ChIP-seq (61, 63) should be complemented with similar 
profiles of coregulators. However, the outcome of such experiments will depend on the 
particular context the animal is in (see (64) for an example of liver targets of GR in fed or 
fasted state). Of course, a better use of available transgenic (knock-in) mouse lines that allow 
functional dissection of GR (and MR) signalling pathways (such as the GRdim/dim (65) or 
CBPKIX mice (66), or mice with altered GR:MR expression ratio (67)) may be used to a larger 
degree. Lastly, the selective receptor modulators that are already available, and of which the 
mechanism is understood, may be used to distinguish between different signalling pathways, 
using straightforward pharmacological approaches. The useful application of existing SGRMs, 
and the development of novel selective modulators for both MR and GR may not only help to 
understand how glucocorticoids modulate brain function, but also may be used in future for 
therapeutic use in stress-related psychopathology. In this regard, our data suggest that 
C108297 and C118335 may be good candidates. 
 
Modulation of nuclear receptor function via targeting of coregulators 
Although the work described here has focused on GR-function, the common mechanism of 
action of nuclear receptors allows for generalization of the model. Because of the broad 
expression of these receptors in many cell types and tissues, targeting with classical agonists/
antagonists has been often proven suboptimal due to side effects. However, many coregulators 
show a more specific and limited expression pattern such as SRC-3 in the brain where it is 
expressed mainly in the hippocampus, cortex and olfactory bulbs and the differential 




Figure 1. Proposed model of the function of selective modulators. A-B. The glucocorticoid receptor is 
bound to its natural ligand corticosterone, dimerized and on chromatin. It can recruit a number of 
different coregulators that interact directly with it (1,4), which can, in turn, recruit other coregulators 
(2,3,5 and 6). These GR-coregulator complexes can then stabilize the transcriptional machinery, 
acetylate histones and activate the transcription of genes G1 and G2. C-D. When GR binds a selective 
modulator it only induces/allows interaction with coregulator 1, but not 4. Therefore, only transcription 
of G1 takes place, while the transcription of G2 is blocked. 
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coregulators may change the directionality of the transcriptional effects of nuclear receptors 
towards the transactivation or transrepression of specific genes. Therefore, the use of ligands 
that result in specific recruitment of coregulators may be advantageous.  An example that 
illustrates this principle is the use of the GR ligands C108297 and C118335 that show 
antagonistic effects without disinhibiting the HPA axis. 
Alternatively, it is possible to modulate the expression of coregulators locally. Because of the 
plethora of interactions between coregulators and various nuclear receptors, global deletion of 
coregulators may not be ideal since it would affect different nuclear receptor-dependent 
pathways and may induce the development of compensatory mechanisms (36, 70). Even 
relatively subtle manipulations may have broader effects and this is something that needs to be 
taken into account for both experimental and therapeutic approaches. 
 
Conclusions 
From the research described here the following conclusions can be drawn: 
-Antisense mediated exon skipping is a feasible method to study the function of genes locally 
in the brain. 
-Shifting of the SRC-1a:SRC-1e expression ratio in favour of SRC-1a changes glucocorticoid 
sensitivity in the CeA, as measured by abrogation of the dexamethasone-induced upregulation 
of CRH expression in this cell group and the impaired fear-motivated behavior. 
-C108297 is a selective modulator of the GR with mixed agonist and antagonist function that 
can antagonize some of the GR-dependent effects without leading to disinhibition of the HPA 
axis. 
-C118335 is a novel GR ligand with a mainly antagonistic profile antagonizing GR-dependent 
effects on gene expression in the brain and impaired consolidation of fear memory. 
-The approaches described here may offer new possibilities for the targeted modulation of GR
-dependent effects in the brain. 
 
Future perspectives 
Despite the work described here, several questions remain unanswered. Future research should 
be oriented to cast light on the function of the SRC-1 splice variants in response to chronic 
stress and particularly whether this manipulation in the CeA would result in alterations of 
HPA function. In addition, since most of the in vivo work regarding SRC-1 function has been 
performed on SRC-1 KO animals which develop well-documented compensatory 
mechanisms, it would be worthwhile to attempt to interfere with total SRC-1 expression either 
via virally-mediated knockdown or with the use of AONs. This strategy would permit to 
investigate the effects of SRC-1 ablation on GR-signaling in the absence of compensatory 
mechanisms. Another relevant open question is the function of SRC-1 in response to stress in 





At a different level there are outstanding questions regarding the gene targets of each splice 
variant/coregulator and which protein cocktail is recruited to each particular context. There 
has been success recently in developing ligands that recruit coregulators in a selective and 
specific manner (71). Therefore, knowledge of coregulator recruitment to the promoters of 
certain genes may assist the development of ligands that can affect the expression of genes 
with high specificity depending on cellular context. 
Coregulators can be involved in epigenetic regulation of gene expression either via own 
activity or via recruitment of appropriate proteins. Thus, studying their epigenetic effects in 
relation to the changes that appear after exposure to stress (72, 73), early life adversity (74) or 
acquisition, consolidation and recollection of traumatic memories (75) may provide a new 
level of possibilities for regulation. 
Finally, development of new selective GR or MR modulators, and better characterization of 
the currently available molecules is promising to open new avenues for the successful 
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The hypothalamus-pituitary-adrenal (HPA) axis and its glucocorticoid end product orchestrate 
the stress response, which is crucial for adaptation and survival. The main effectors are 
glucocorticoid hormones, which act via by the mineralocorticoid receptors (MRs) and 
glucocorticoid receptors (GRs) and involves modulation of gene expression. Here we focus on 
the GR. One target gene of the GR is the Crh gene, which is expressed in the paraventricular 
nucleus of the hypothalamus (PVN) and the central nucleus of the amygdala (CeA). In the 
PVN, GR mediates the feedback action of the glucocorticoids on stress-induced CRH 
synthesis and release, while in the central amygdala the glucocorticoids are involved in the 
regulation of expression of emotional states. 
Given the pleiotropic effects of glucocorticoids, treatment with GR agonists or antagonists 
may be accompanied by side effects. Therefore, the ability to modulate specific GR-dependent 
pathways may provide an opportunity to develop more selective drugs. One possibility of 
increased selectivity might be to target proteins that interact with the GR.  
In order to mediate the genomic effects of glucocorticoids the GR often needs to operate in 
synergy with other proteins (coregulators) that are involved in transcriptional modulation. 
Steroid receptor coactivator 1 (SRC-1) is a coregulator of the GR that is necessary for the 
regulation of Crh expression. Its two isoforms SRC1a and SRC1e are encoded by the Ncoa1 
gene. SRC-1a lacks a SRC-1e specific exon. The two isoforms differ in their activities and 
distribution in the brain: SRC-1a is more abundant in the PVN and can potentiate repression at 
the Crh promoter, whereas SRC-1e is more abundant in the CeA and lacks repressive 
capacity. 
In this thesis studies are reported aimed to modulate the function of the GR by targeting GR-
coregulator interactions. To achieve this goal, we used two different approaches. Firstly, we 
manipulated the splicing of SRC-1 with antisense oligonucleotides (AONs) administered in 
the CeA to change the relative expression of the two SRC-1 splice variants. Secondly, we 
used two novel GR ligands that allowed certain GR-coregulator interactions while preventing 
others, thus resulting in a mixed GR-coregulator interaction profile, which exhibited a 
spectrum of both agonist and antagonist activities. 
In chapter 1 the role of the HPA axis was introduced with focus on the effects of 
glucocorticoids on the regulation of Crh expression and the function of the amygdala. 
Moreover, we introduced the possibility to manipulate gene expression and splicing by 
antisense oligonucleotides for the study of the importance of GR-coregulator interactions. 
In chapter 2 we described the validation of the antisense-mediated exon skipping of SRC-1 in 
vivo in the CeA, in terms of cellular uptake, efficacy and potential immunostimulatory effects. 
After a single injection with either a control AON or saline in the mouse CeA, we investigated 
the uptake by neurons and possible immune responses induced by this treatment in the brain. 
The results showed that AONs were readily taken up by neurons in the brain and there were 
no differences between AONs and saline with regard to the elicited immune responses 
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following a single injection in the CeA.  
Subsequently, we investigated the effects of an AON targeting the SRC-1e specific exon on 
the expression ratio of the two SRC-1 splice variants. Using laser microdissection, the cells 
that had taken up AONs were collected and the expression of SRC-1a, SRC-1e, total SRC-1 
and GR was quantified with qPCR. Our results showed that the SRC-1e specific AON 
treatment resulted in an increased SRC-1a:SRC-1e expression ratio, three and seven days post-
injection. This shift in favour of SRC-1a was not accompanied by differences in expression of 
total SRC-1, SRC-2 or GR in the CeA.  
These results indicate that AON-mediated exon skipping is an efficient method to manipulate 
the splicing of the NcoA1gene with limited adverse effects. 
In chapter 3, we described the effects of shifting the expression ratio of SRC-1a:SRC-1e in 
favour of SRC-1a, in the CeA, on behavior and regulation of Crh expression by 
glucocorticoids. We found that animals injected with the AON targeting the SRC-1 specific 
exon showed higher locomotion in an open field test, which was positively correlated with the 
SRC-1a:SRC-1e expression ratio. We also observed impaired contextual fear memory 
consolidation in a fear conditioning paradigm. The differences in behavior were observed 
despite the lack of effects on HPA axis activity either at basal conditions or after exposure to a 
stressor. Moreover, SRC-1 exon skipping completely blocked the dexamethasone-induced crh 
expression in the CeA. The expected downregulation of crh expression in the PVN in response 
to dexamethasone was still present suggesting that an altered SRC-1a:SRC-1e expression ratio 
in the CeA does not affect Crh expression in the PVN. 
The effects on behavior, particularly on fear memory consolidation, and (foremost) the 
abrogation of dexamethasone-induced upregulation of Crh expression in the CeA suggest a 
differential sensitivity of the CeA to glucocorticoids as a result of the manipulation of SRC-1 
splicing. In conclusion, targeted changes of the available pool of coregulators may result in 
preferential activation or repression of specific pathways in the brain. 
In parallel, we tried to selectively modulate glucocorticoid responsive pathways with 
pharmacological manipulations of the GR. In Chapter 4 the experiments were reported with a 
novel selective GR ligand (C108297).  We tested the effects of C108297 on GR-coregulator 
interactions, gene expression in the hippocampus, HPA axis activity, Crh expression in the 
CeA and PVN, as well as adult neurogenesis and fear memory consolidation. We found that 
C108297 showed agonism and antagonism, but in different pathways. It induced a mixed GR-
coregulator interaction profile, allowing some of the interactions while inhibiting others. 
C108297 had agonistic effects on fear memory consolidation, as well as weak agonistic effects 
on the regulation of the HPA axis in response to stress. On the other hand, C108297 showed 
antagonism on the expression of Drd1a in the hippocampus and it blocked the effects of 
corticosterone treatment on adult neurogenesis. Taking into account the mixed properties of 
C108297, we can conclude that the compound acts as selective modulator rather than an 
agonist or antagonist.  
The pharmacological profile of C108297 suggests a potential improvement over the current  7 
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treatment regimens with GR antagonists. Its lack of affinity for other nuclear receptors may 
exclude some of the adverse effects associated with the current GR antagonists such as 
RU486. Moreover, the mixed agonist and antagonist effects indicate the differential impact of 
C108297 on different GR-dependent pathways, which may also result in a more specific 
regulation. Taken together, the current results provide a proof-of-principle for the use of 
selective GR ligands to limit the effects of hypercortisolemia. 
In chapter 5, the findings with another novel GR ligand (C118335) were described. C118335 
lacks affinity for the progesterone receptor, but has retained low affinity for the MR. C118335 
induced a distinct GR-coregulator interaction profile. Most of the interactions were blocked. 
However, in contrast to the classical antagonist RU486, it did not recruit corepressors, but 
induced, to some extent interactions with SRC-1 NR-boxes. Interestingly, C118335 induced 
considerable interactions with the SRC-1a specific NR-box. At the functional level, C118335 
had antagonistic effects on the regulation of gene expression by glucocorticoids in the 
hippocampus and the striatum, while it impaired fear memory consolidation. Despite its 
antagonist properties, C118335 did not lead to disinhibition of the HPA axis under mild stress.  
Similarly to C108297, C118335 may also represent an improvement to current therapeutic 
agents in relation to hypercortisolemia, although the effects of the two compounds differ 
significantly, particularly regarding their effects on memory consolidation and gene 
expression. Nevertheless, the weak MR affinity of C118335 may also be relevant in such 
conditions. 
Finally, in chapter 6, we attempt a synthesis of the concepts presented in this thesis. A model 
emerges where GR-coregulator interactions have a prominent role in the modulation of GR-
dependent pathways. These interactions can be, in turn, modulated in two different ways: 
either via manipulation of the availability of coregulators or their splicing (chapters 2 and 3), 
or by treatment with ligands that can alter the recruitment of coregulators by the GR (chapters 
4 and 5). In this process, antisense-mediated manipulation of splicing was shown to be an 
effective experimental tool to study gene function in the brain (chapter 2). Moreover, a step 
was made towards the clarification of the in vivo role of the two SRC-1 splice variants in 
relation to regulation of crh expression and fear memory consolidation (chapter 3).  
In addition, two novel compounds were tested, both of which had distinct properties compared 
to GR agonists or the GR antagonist RU486. C108297 (chapter 4) acted as a selective 
modulator with agonist as well as antagonist properties. C118335 (chapter 5) showed 
antagonism in most functions tested. In conclusion, the approaches described here may offer 





Glucocorticoïd hormonen reguleren als eindproduct van de hypothalamus-hypofyse-bijnier 
(HPA) as de reactie op stress die cruciaal is voor aanpassing en overleven van het organisme. 
Deze hormonen oefenen doorgaans hun werking uit door binding aan mineralocorticoïd 
receptoren (MR) en  glucocorticoïd receptoren (GR) via modulatie van genexpressie. Ons 
werk heeft vooral betrekking op de effecten die via de GR tot stand komen.  
Omdat glucocorticoïd hormonen vele processen in het hele lichaam beïnvloeden, kan 
toediening van GR agonisten (activatoren) en antagonisten (blokkers) met veel bijwerkingen 
gepaard gaan. Modulatie van specifieke GR-afhankelijke signaaltransductie biedt een 
mogelijkheid om selectief werkende glucocorticoïden te ontwikkelen. Daartoe zouden 
eiwitten, die specifieke glucocorticoïd effecten bij GR-activatie tot stand brengen, beïnvloed 
moeten worden. Voor de GR effecten die via gentranscriptie verlopen is daarvoor de klasse 
van coregulator eiwitten van groot belang.  
Het eiwit Steroïd Receptor Coactivator-1 (SRC-1) is zo’n coregulator. SRC-1 is van belang 
gebleken voor specifieke effecten die via GR verlopen in de hersenen. Het betreft regulatie 
van het Crh gen, dat codeert voor corticotropin releasing hormone (CRH) dat de reactie op 
stress orkestreert.  In de nucleus paraventricularis van de hypothalamus leidt GR-activering tot 
onderdrukking van CRH, in het kader van negatieve terugkoppeling binnen de HPA as. In de 
centrale nucleus van de amygdala leidt GR-activering juist tot stimulering van CRH productie, 
en dit is van belang voor expressie van emoties. Zonder SRC-1 vindt noch de stimulatie noch 
de remming van CRH door glucocorticoïden plaats. 
Het SRC-1 eiwit komt in twee varianten voor, SRC-1a en SRC-1e. Dit zijn zogenaamde splice 
varianten van hetzelfde gen, het Ncoa1 gen (voor ‘nuclear receptor coactivator 1’). Het 
vóórkomen van deze  twee varianten verschilt tussen hersengebieden. SRC-1a is veel 
aanwezig in de hypothalamus, waar het de expressie van het Crh gen onderdrukt. SRC-1e 
komt relatief meer voor in de amygdala en blijkt niet in staat tot onderdrukking van het Crh 
gen.  
De doelstelling van het onderzoek dat in dit proefschrift beschreven is, was om de functie van 
GR te moduleren door de interactie met specifieke coregulatoren te manipuleren in de 
hypothalamus en amygdala van proefdieren. Hiertoe zijn twee benaderingen gebruikt. Ten 
eerste hebben we de verhouding tussen de hoeveelheid SRC-1a en SRC-1e gemanipuleerd met 
‘exon skipping’. Kleine stukjes DNA (antisense oligonucleotiden of AONs) zijn hiertoe 
toegediend in de amygdala van muizen om het ‘splicing’ proces te beïnvloeden en daarmee de 
GR-transductie sterker via de SRC-1a variant te laten verlopen. Ten tweede hebben we twee 
nieuwe synthetische steroïden gebruikt die selectief binden aan de GR. Waar GR bezetting 
door lichaamseigen hormonen (‘volle agonisten’) leidt tot een groot aantal GR-coregulator 
interacties, staan de twee nieuw gebruikte verbindingen maar een klein aantal van dergelijke 
interacties toe. Dat leidt tot een GR-coregulator profiel dat het midden houdt tussen dat van 
een agonist en een antagonist van de receptor. Daarmee bootsen deze stoffen sommige 




In hoofdstuk 1 is de rol van de HPA-as bij aanpassing aan stress beschreven, met nadruk op 
de effecten die glucocorticoïd hormonen hebben op de regulatie van het Crh gen, en de functie 
van de amygdala. Bovendien wordt het principe van manipulatie van genexpressie via ‘exon 
skipping’ besproken in het kader van het onderzoek naar stress en GR functie. 
In hoofdstuk 2 is de werkzaamheid en eventuele ongewenste bijwerkingen beschreven van 
exon-skipping na AON-behandeling in het muizenbrein. Na één injectie van AONs in de 
centrale nucleus van de amygdala, zijn de effecten 3, 7 en 14 dagen na de injectie vastgesteld. 
De AONs bleken opgenomen te worden in de zenuwcellen en er werd niet meer schade of 
aspecifieke weefselreacties waargenomen dan wanneer er een fysiologisch zout oplossing 
toegediend werd. De bepaling van de werkzaamheid werd gedaan door met de laser 
microdissectie techniek kleine hoeveelheden weefsel te verzamelen, waarin door fluorescente 
de opname van AONs gemarkeerd was. In dat weefsel werd de expressie (het vóórkomen) van 
mRNA coderend voor de relevante SRC-1 varianten en voor totaal SRC-1 mRNA bepaald met 
de kwantitatieve PCR techniek. De resultaten lieten zien dat het zinnig is om de exon-skip 
methode te gebruiken teneinde de rol van SRC-1 varianten in het muizenbrein te onderzoeken. 
In hoofdstuk 3 zijn vervolgens de effecten beschreven van een veranderde verhouding tussen 
de SRC-1a en SRC-1e varianten in de amygdala (ten gunste van SRC-1a) op stress-gerelateerd 
gedrag per se, en op de gevoeligheid van de centrale amygdala voor glucocorticoïd hormonen 
wat betreft expressie van het Crh gen, en gedragseffecten van deze hormonen.  
De dieren hadden na behandeling met AONs veranderde gedragsreactiviteit in een ‘open veld’ 
test, en ook minder herinnering aan een aversieve situatie in een klassiek 
conditioneringsexperiment. Deze gedragsveranderingen gingen evenwel niet gepaard met 
verschillen in hormonale stressreactie. Opmerkelijk was dat na AON behandeling de dieren in 
het geheel niet meer reageerden op behandeling met glucocorticoïden, wat betreft regulatie 
van het Crh gen in de amygdala. Ook gedragsveranderingen die in controle-dieren gezien 
werden na hormoonbehandeling traden niet op na exon-skipping.  
Deze resultaten laten zien dat de beschikbaarheid van coregulatoren bepalend is voor de 
effecten van glucocorticoïden op stress-circuits in het brein. Omdat coregulatoren specifiek 
betrokken zijn bij een deel van de effecten die uitgeoefend worden via de GR, betekent dit dat 
de effecten van het glucocorticoïd hormoon cortisol gestuurd kunnen worden door manipulatie 
van de beschikbaarheid van coregulatoren. 
In hoofdstuk 4 is als alternatief voor de exon-skipping de farmacologische aanpak beschreven. 
Hiertoe is een nieuwe selectieve ligand van de GR gebruikt, de synthetische verbinding 
C108297. Aan de hand van de moleculaire interacties die optraden tussen de GR en 
verschillende coregulator eiwitten, kon voorspeld worden dat deze stof een zogenaamde 
selective modulator is, die zowel agonisme als antagonisme kan vertonen, afhankelijk van het 
specifieke proces. Hier is dus niet de beschikbaarheid van coregulatoren in de cel bepalend, 
maar de affiniteit van de door ligand gebonden receptor voor specifieke coregulatoren. 
C108297 bleek inderdaad zowel als agonist als antagonist te werken op GR-afhankelijke 
genexpressie in de hippocampus van de rat. Er was sterk agonisme bij consolidatie van 
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angstherinneringen, zwak agonisme op de activiteit van de HPA-as, maar functioneel 
antagonisme op Crh expressie in de amygdala en neurogenese in de hippocampus.  
Dit zijn de eerste resultaten die laten zien dat ‘selectieve modulatoren’ van de GR werkzaam 
kunnen zijn in hersengebieden die betrokken zijn bij de aanpassing aan stress. Zulke stoffen 
kunnen nuttig zijn om de effecten van glucocorticoïden beter te begrijpen, maar ook om – 
waarschijnlijk eerder dan de AONs die gebruikt werden in de eerder beschreven proeven – in 
klinische omstandigheden met een mate van selectiviteit GR-afhankelijke processen te 
beïnvloeden bij stress-gerelateerde ziekte. 
In hoofdstuk 5 is een andere nieuwe GR ligand, C118335 beschreven. Ook deze stof 
induceert een uniek interactie-profiel tussen de GR en haar coregulatoren. De interacties lijken 
op die van de meest gebruikte antagonist (mifepristone of RU486), maar suggereren een 
hogere mate van agonisme via interacties met enkele coregulatoren. Bovendien heeft C118335 
ook affiniteit voor de MR.  
Functioneel werkte C118335 met name als antagonist wat betreft regulatie van klassieke GR-
afhankelijke genen in de hippocampus en het striatum. De stof had een verrassend sterk 
remmend effect op consolidatie van angstherinneringen. Ondanks dit antagonisme, werd geen 
ontremming van de HPA-as waargenomen.  
C118335 is daarmee een ‘selectieve modulator’ met een meer antagonist-achtig 
werkingsprofiel, die evenwel geen duidelijk antagonisme laat zien op de HPA-as. Ook kunnen 
stoffen als deze experimenteel en – mogelijk – klinisch gebruikt worden om ongewenste 
effecten van hoge cortisolspiegels tegen te gaan, waarbij een groot aantal zowel MR- als GR 
afhankelijke effecten geblokkeerd zullen worden. 
Ten slotte heb ik getracht in hoofdstuk 6 tot een synthese te komen van de concepten die in 
eerdere hoofdstukken gepresenteerd zijn. Centraal hierbij is het idee dat GR- (en MR-) 
coregulator interacties selectief te activeren zijn, en dat daarmee gewenste en ongewenste 
effecten van glucocorticoïden te scheiden zijn, ook die effecten die via één receportype 
gemedieerd worden. Dit principe is op twee manieren aangetoond.  
Eén specifieke manier is om coregulator-beschikbaarheid te beïnvloeden via exon-skipping, 
lokaal in de hersenen. De specificiteit betreft hier echter met name het GR-signaal dat 
beïnvloed wordt, omdat de coregulatoren vaak ook voor andere signaaltransductie processen 
van belang zijn. Een andere meer grofmazige manier is het gebruik van selectieve 
receptormodulatoren. Hierbij wordt van alle mogelijke mechanismen die via de receptor 
verlopen een deel geactiveerd, en een ander deel niet. Deze laatste benadering is misschien 
minder specifiek dan het manipuleren van één bepaalde coregulator, maar waarschijnlijk 
gemakkelijker toe te passen in het onderzoek en – wellicht – de kliniek. Beide benaderingen 
zijn evenwel uitermate geschikt om de rol van MR en GR bij aanpassing aan stress te 
onderzoeken, en bieden derhalve duidelijke aanknopingspunten om nieuwe geneesmiddelen te 
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